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Introduction 
 
All organisms must maintain a complex and dynamic equilibrium, or homeostasis, 
which is constantly challenged by internal and external forces termed stressors. Stress 
occurs when homeostasis is threatened or perceived to be so; homeostasis is 
reestablished by various physiological and behavioral adaptive responses. During 
evolution the organism has developed a stress-system to deal with factors which may 
disturb homeostasis, of which the Hypothalamus-Pituitary-Adrenal (HPA) axis is an 
important part. Neuroendocrine hormones, such as cortisol, play a major role in the 
maintenance of basal homeostasis as responses to threat, and are involved in the 
pathogenesis of diseases characterized by dyshomeostasis.1;2  
The stress-system needs to have a far-reaching power over the metabolism of the 
body, because in times of crisis the body should be able to acutely redirect metabolism 
to enable a fight, flight or freeze reaction. Especially in humans, along with the 
development of the stress system, psychological stress factors became more 
important, such as fear anticipation. It is generally assumed that the organism did not 
develop a new stress system to cope with these psychological stressors, but used the 
already working stress-system, again with the HPA axis as an important part.  
If the stress-system plays an important role in psychological stress, it is to be 
expected that depression and anxiety disorders are accompanied by dysfunctions of 
this system.3-5 This hypothesis has been tested, mainly in research using cortisol 
concentrations in blood or saliva as marker for the function of the hypothalamus-
pituitary-adrenal (HPA) axis. Thus far, the results were inconsistent: hypercortisolism, 
hypocortisolism and normal cortisol levels were found.6-14 
Before one can conclude that thus the HPA axis and the stress-system are not 
involved in depression and anxiety disorders, several other explanations should be 
considered. Cortisol may not be the right marker for the stress-system in general or 
the HPA axis in particular. As cortisol has such a central place in the stress-system this 
is not very probable. Besides, the problem is not that abnormal cortisol levels are 
absent in patients with depressive and anxiety disorders: Abnormalities have been 
found repeatedly. The problem is that the abnormalities were inconsistent. Therefore, 
another possibility should be considered, i.e., that the phenotype or clinical picture is 
described insufficiently. This is less improbable than it may seem: the validity of the 
most used diagnostic classification system, the DSM-IV, has been questioned 
frequently. To date, the DSM has focused solely on face or clinical validity, the 
assertion that the diagnoses correspond to clinicians’ subjective views of a disorder. 
This is a weak form of validity only requiring consensus among clinical experts. One 
common form of validity is expressed by sensitivity and specificity, which are both 
low for DSM-IV diagnoses due to the extensive comorbidity, the high within-category 
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heterogeneity, and the overlap of DSM-IV diagnoses by sharing criteria. Ideally, the 
validity of a diagnosis is determined by the correlation between the diagnosis and 
another criterion of the disease, for instance a biological parameter, which is 
considered as ‘gold standard’. As discussed above, such a gold standard has not been 
found.  
In this thesis we explore whether a dimensional approach to describe the clinical 
picture is a better way to disentangle the relationship between phenotype and HPA 
axis functioning than the DSM-IV categories. In addition to and as a consequence of 
that starting point, not the clinical picture (diagnosis or dimension) was central in our 
studies, but cortisol levels. In other words, we investigated per dimension to what 
extent differences in scores on that dimension correlated with cortisol levels and not 
which cortisol levels were found in major depression and which in anxiety disorders. 
In depression and anxiety also abnormalities in metabolic and immune parameters 
have been found, but again the results were inconsistent. To date, none of the 
metabolic and immune markers were sufficiently specific to contribute to the 
diagnosis of major depression.15 Therefore, we also investigated the relation of the 
cortisol levels with those biological markers, hoping to find a more consistent picture.   
In conclusion, we moved from an approach that puts psychiatric diagnosis in the 
center to an approach that puts the HPA axis in the center (see figure 1). In the 
following part of this introducing chapter, background information and an outline of 
this thesis are presented. 
 
Phenotype: 
▪ DSM-IV
Phenotype:
▪ comorbidity
▪ dimensions
Immune system: 
▪ C-reactive protein
Metabolic system: 
▪ lipid metabolism 
▪ adiposity
Metabolic system: 
▪ lipid metabolism 
▪ adiposity
Immune system: 
▪ C-reactive protein
HPA-axis: 
▪ cortisol
HPA-axis:
▪ cortisol
 
Figure 1. Structure of thesis 
Associations between HPA axis function, phenotypic characteristics, metabolic and immune factors in 
depression and anxiety disorders. Associations might be bidirectional and may also exist between ‘nodes’, but 
are left out in the picture for the purpose of clarity. 
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Major depressive disorder and anxiety disorders 
Depression and anxiety disorders are invalidating affective disorders accompanied by 
diminished functioning or well-being and increased mortality. Major depressive 
disorder (MDD) is characterized by a depressed mood and/or the loss of interest and 
pleasure in nearly all activities. In addition to these essential features, alterations in 
appetite, sleep disturbances, psychomotor changes, fatigue and decreased energy, 
feelings of worthlessness, cognitive problems (e.g. inability to make decisions), and 
thoughts of death are considered to be characteristics symptoms. For a diagnosis 
according to DSM-IV (APA, 1994), one of the essential features together with at least 
four additional symptoms have to be present most of the day, nearly every day, for at 
least two weeks. MDD is a common psychiatric disorder, with a 12 month prevalence 
of 5.8% in the Netherlands.16 
Anxiety disorders are characterized by an excessive feeling of overwhelming 
anxiety, irrational fear and avoidance behaviour. The anxiety is often accompanied by 
physical symptoms such as sweating, cardiac disturbances, diarrhea or dizziness. 
Anxiety disorders include panic disorder, social anxiety disorder, post-traumatic stress 
disorder (PTSS), obsessive-compulsive disorder, generalized anxiety disorder, and 
specific phobia. Each anxiety disorder has specific symptoms, but all the symptoms 
cluster around excessive, irrational fear and threat. The 12 month prevalence of all 
anxiety disorders is 12.4% in the Netherlands.16 Depressive and anxiety disorders are 
considered as stress-related disorders, marked by a dysfunction of the HPA axis.5 
 
Stress 
Stress and stress vulnerability are assumed to play major etiological roles in depression 
and anxiety disorders. The acute stress response is reflected in the rapid activation of 
the sympathetic nervous system, which leads to the release of epinephrine and 
norepinephrine. The sympathic pathways (epinephrine) elevate heart rate, blood 
pressure, respiration, glucose synthesis and cognitive arousal/attention. 
Simultaneously, the parasympathic pathways (e.g., norepinephrine and other 
catecholamines) are activated leading to a decrease in food intake, sleep and sexual 
drive. As part of the stress response, the hypothalamus releases corticotrophin-
releasing hormone (CRH) inducing the release of adrenocorticotropic hormone 
(ACTH) from the pituitary gland, which stimulates the adrenal cortex to produce and 
secrete corticosteroids. This leads to elevated circulating levels of corticosteroids, in 
man mainly cortisol (figure 2). The acute stress response is adaptive to homeostasis. In 
the long term, chronic or repeating stress may impair physiological functions, such as 
growth, reproduction, metabolism, and immunocompetence, and imposes an 
increased risk for depression and anxiety disorders.17-19  
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The underlying risk for the development of depression and anxiety disorders can 
be conceptualized as an accumulation of daily hassles, lifestyle, and major life events 
that interact with the genetic constitution and predisposing early life experiences.5 The 
relationship between life stress and depressive disorders is well established.17 Post 
(1992) asserted that the nature of the relationship between stressful life events and 
depression changes as function of the longitudinal course of the disease.20 Post’s basic 
premise is that the first episode of a depressive disorder is more likely to be preceded 
by major psychological stressors than subsequent episodes. At the basis of this 
premise are two distinct models that offer potential mechanisms of this empirical 
observation: behavioral stress sensitization and electrophysiological kindling. Stress 
sensitization is observed by the fact that less and less life events are needed to elicit 
depression across the course of the disorder. Kindling is the observation that after an 
initial sensitization to stressors, recurrences of depression occur autonomously, in the 
absence of stressors.21 In a recent meta-analysis, evidence was provided that first 
onsets of depression were more likely than recurrences to be preceded by severe life 
events, supporting Post’s view.22  
 
HPA axis 
The HPA axis is an important neuroendocrine system involved in stress coping. HPA 
axis activity is predominantly studied in this thesis by measuring one of its final 
products: cortisol, the main stress hormone in humans. In reaction to both physical 
and psychological stress, CRH is released from the paraventricular nucleus in the 
hypothalamus. As a consequence, a neuroendocrinological cascade is initiated, with 
CRH stimulating the release of ACTH from the pituitary gland. In turn, ACTH binds 
to receptors in the outer cortex of the adrenal glands, resulting in the secretion of the 
steroid hormone cortisol (Figure 2).  
Plasma cortisol release is tightly regulated by negative feedback at the level of the 
pituitary, hypothalamus and hippocampus. Cortisol acts through binding to 
mineralocorticoid (MR) and glucocorticoid receptors (GR). Low levels of cortisol are 
sufficient to occupy the high-affinity MR, a receptor involved in the maintenance of 
homeostasis, which exerts tonic inhibition of the HPA axis. During stress, when 
cortisol levels are high, also the low-affinity GR are occupied. The GR mainly acts to 
prevent overshoot of primary defense reactions and shuts of the HPA axis.  The 
balance between MR and GR modes is thought to be essential for cell homeostasis, 
mental performance, and health. This ‘yin-yang’ concept in stress regulation is 
fundamental for genomic strategies to understand the mechanistic underpinning of 
corticosteroid-induced stress-related disorders such as depression and anxiety 
disorders.5;23 
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Figure 2. Hypothalamic-pituitary-adrenal axis 
 
Cortisol release shows a clear diurnal rhythm. Cortisol levels peak about half an hour 
after awakening, with a 50% to 100% increase in cortisol levels compared to the levels 
during the rest of the day. The lowest level are found around midnight (Figure 3).24 
The main effect of cortisol is an increase of blood glucose levels via glucogenesis 
(glucose synthesis) and glycogenolysis (glucose release from storage). During the acute 
phase of the stress response the release of cortisol result in a replenishment of 
depleted energy levels. Later it provides energy for the long-term demands. 
The integrity of the HPA axis can be evaluated using a variety of paradigms in 
basal and challenge conditions. As indicator of basal HPA axis function the saliva 
cortisol day curve is assessed in many studies. In addition, several neuroendocrine 
challenge tests have been developed to study HPA axis activation. A formerly 
frequently used test is the dexamethasone suppression test (DST), which examines 
whether negative feedback processes can be inhibited by the oral administration of 
dexamethasone (DEX) (usually 0.5 to 1.0 mg). DEX pretreatment normally results in 
a suppression of pituitary adrenocorticotropic hormone (ACTH) release and thus 
reduces secretion of cortisol from the adrenals. However, if DEX is given to 
hypercortisolemic individuals, cortisol suppression may be incomplete, resulting in less 
DEX suppression (DST-nonsuppression).  
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Figure 3. One example of a saliva cortisol day curve 
 
In the mid nineties the DEX/CRH test was introduced, to examine HPA activity 
under the condition of suppressed glucocorticoid feedback. The application of the 
DEX/CRH test requires individuals to take 1.5 mg DEX orally at 23:00h on the night 
before the test day. On the day of the test itself, 100 micrograms human CRH are 
administered at 15:00h intravenously as a bolus, and blood samples for the 
determination of plasma cortisol and ACTH are drawn every 15 min from 15:00h (pre 
CRH)  to 16:45h. Excessive ACTH and cortisol responses are indicative of a disturbed 
negative-feedback regulation and an overactive HPA system as is frequently seen in 
stressed and/or depressed individuals.25 The DEX/CRH test has been reported to be 
more sensitive (above 80%) than the DST (about 20-50%) in differentiating MDD 
patients from healthy controls and it has therefore been argued that the DEX/CRH 
test unveils subtle HPA axis disturbance not detected by the DST.6;26 
 
HPA axis dysfunctions in depression and anxiety disorders 
Previous studies show inconsistent and contradictory findings regarding HPA 
dysfunctions in patients with depression and anxiety disorders. Hyperactivity of the 
HPA axis is a frequent finding in MDD.9;13 Approximately 50-60% of patients with 
MDD show higher baseline ACTH and cortisol levels and diminished negative 
feedback, resulting in an escape from DEX suppression in the DST. After challenge 
with CRH under pretreatment with DEX, depressed patients show increased ACTH 
and cortisol responses to CRH.6;25 However, minor or no alterations of the HPA 
system were found in dysthymic and chronically depressed patients.8;10 Studies in 
outpatients and community populations have also provided limited evidence of HPA 
axis dysfunctions in depression.27-30 Furthermore, in older depressive patients, 
associations were found with hypercortisolism as well as with hypocortisolism, 
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indicating the presence of a non-linear, U-shaped association between depression and 
cortisol.31;32  
Studies in primary anxiety disorder patients have revealed less robust HPA axis 
dysregulations. The majority of the studies suggest that basal cortisol and ACTH 
concentrations are unaltered.9 In panic disorders patients, elevations of basal cortisol 
and rates of nonsuppression in DST are reported that are slightly elevated compared 
to normal subjects, but much lower than those observed in depressive patients. 
Furthermore, higher HPA axis responsiveness was found in panic disorder patients 
compared with healthy controls following injection with CRH, and to CRH following 
DEX pretreatment.7;11 Patients with social anxiety disorder did not differ from 
controls in basal 24-h urinary and salivary cortisol levels 14;33;34 and in response to 
DST.14;34 However, in response to the Trier Social Stress Test, patients with social 
anxiety disorder had a significantly larger cortisol response than controls.35 Patients 
suffering from PTSD mainly show lower baseline cortisol levels, increased CRH 
concentrations, increased sensitivity to the suppressive effects of DEX, and blunted 
ACTH response to CRH stimulation test. These findings indicate enhanced negative 
feedback capacity and an increased sensitivity of glucocorticoid receptors in the HPA 
system.36 Elevated cortisol levels were also found in PTSD studies, specifically in 
patients with comorbid depression.37 
 
Phenotype 
The phenotype refers to the observable characteristics or symptoms of an individual. 
In psychiatry, different phenotypic approaches are used, but the Diagnostic and 
Statistical Manual of Mental Disorders (DSM)-IV classification system is most 
commonly used. A major problem of this categorical approach to phenotyping is the 
high comorbidity and low specificity due to the huge overlap in symptoms between 
depression and anxiety disorder diagnoses. 
 
Psychiatric comorbidity 
One explanation for the variability and inconsistencies in results of studies on 
dysfunctions of the HPA axis in patients with depression and anxiety disorders is 
comorbidity. A large epidemiological survey in the United States showed a lifetime 
prevalence rate for comorbid depression and anxiety disorders of 41%.38;39 Feinstein 
first introduced the term comorbidity in the medical literature in 1970 (Feinstein, 
1970). Comorbidity refers to two or more distinct co-occurring psychiatric disorders 
in an individual patient. Comorbidity of depression and anxiety disorders is widely 
understood to be associated with increased severity, persistence, and functional 
impairment.40 There might be several possible explanations for the high frequency of 
comorbidity between anxiety disorders and (often temporally secondary) depressive 
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disorders, e.g., anxiety disorders could be a causal risk for depressive disorders, or 
anxiety and depressive disorders could be both the consequence of a common 
underlying factor. The last assumption is strengthened by the evidence of a shared 
genetic vulnerability for anxiety and depressive disorders.41 As a consequence, the use 
of categorical DSM IV axis I diagnoses to search for specific underlying 
neuroendocrine dysfunctions might have limited potential, because depression and 
anxiety disorders may share some etiological factors. 
A small number of studies on HPA axis function included a separate group of 
patients with comorbid depression and anxiety disorders, in addition to a group of 
patients who suffered from only the pure disorder (usually the depressive disorder). In 
the DST, patients with comorbid panic disorder and depression show higher rates of 
nonsuppression than those with pure panic disorder; the rates of the comorbid group 
were comparable to the rates seen in pure depression.42;43 Patients with mixed anxiety 
and depressive disorder do also show DST nonsuppression rates similar to those seen 
in depression.44 Mixed findings were found for PTSD with comorbid depression. 
Some studies showed low baseline cortisol and enhanced negative feedback to 
DEX,45;46 whereas others showed increased baseline cortisol.37 When using a 
psychological challenge test, such as the Trier Social Stress Test, ACTH was 
significantly higher in depressed patients compared to controls, and cortisol showed a 
trend in the same direction. However, this increase was completely due to those 
depressed patients who also had a comorbid anxiety disorder. The pure depressed 
patients did not show an increase.47  
To summarize, studies on psychiatric comorbidity and the HPA axis, mostly found 
that depression is more robustly linked to HPA axis dysregulation than anxiety is. 
Depression might thus  ‘dominate’ the neuroendocrine picture when disorders are 
comorbid.30 However, when using a psychological challenge test, the presence of an 
anxiety disorder seems to modify the effect of the presence of depression on cortisol 
levels. As far as we know, no studies were done on the influence of psychiatric 
comorbidity on the responsivity to the more recently developed DEX/CRH test in 
patients with depression and anxiety disorders. 
 
Categories versus dimensions 
One way of handling the problem of comorbidity in psychiatric research might be by 
looking for alternative approaches to phenotyping. Although the categorical DSM-IV 
diagnoses have resulted in a significant improvement in worldwide communication 
among clinicians and make outcome of research worldwide comparable,48 one of the 
disadvantages is the use of a threshold level of symptoms in deciding whether a 
diagnosis is present or not. Furthermore, there is a high amount of overlap in 
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symptoms between diagnoses. A problem related to the overlap is the already 
discussed high prevalence of comorbidity.  
Assessing dimensions might be an alternative phenotypic approach to categorical 
DSM-IV diagnosing. A dimensional approach has several advantages. Firstly, 
dimensions replace categorical comorbidity by providing patient-specific diagnostic 
profiles. Secondly, dimensions might be better suited to help us understand 
relationships with biological, anatomical and genetic factors, because genetic 
transmission of psychopathology may operate at the level of individual dimensions or 
symptoms rather than at diagnostic or syndromal levels.49 Lastly, dimensions provide 
quantitative scores, with which a more adequate description of symptom severity is 
possible, the sensitivity and statistical power is increased and, of course, the 
dichotomy of categorical diagnoses is avoided.  
Several dimensional models have been proposed for assessing depression and 
anxiety disorders, such as the approach-withdrawal model, the valence-arousal model, 
and the tripartite model.50 All of these models posit that depression and anxiety share 
a common distress dimension, whereas other dimensions discriminate these disorders.  
A. Clark and Watson’s tripartite model is designed to handle the high 
comorbidity rates of depression and anxiety disorders by taking into account 
overlapping as well as distinct features of anxiety and depression 51. The 
model posits two broad factors of temperament, namely positive affect and 
negative affect. Positive affect includes traits such as enthusiasm, excitement 
seeking, gregariousness, and energy. Negative affect includes emotions such 
as sadness, guilt, hostility, uneasiness, fear, and self-dissatisfaction. The third 
dimension of the tripartite model is autonomic arousal. Its symptoms are 
physiological and include symptoms such as dizziness, shortness of breath, 
racing heart, and shaky hands. Low positive affect (also called the ‘anhedonic 
depression’ dimension) is thought to be rather specific for depression, 
whereas autonomic arousal (also called the ‘anxious arousal’ dimension) is 
rather specific for anxiety, as is seen in panic disorder. High negative affect 
(also called the ‘general distress’ dimension) is a non-specific factor that 
relates to both depression and anxiety, and is seen as a measure of severity of 
psychopathology.  
B. The approach-withdrawal system of Davidson and colleagues posits two 
separate systems of motivation and emotion: an approach and a withdrawal 
system. While the tripartite model is proposed as part of a larger 
biobehavioral system, the core of this model is an affective system. The 
approach system is viewed as being responsible for the generation of positive 
affect, which is elicited when one moves towards an incentive, reward or 
positive stimulus. Activation of the withdrawal system is also hypothesized to 
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elicit arousal. The withdrawal system is purported to be responsible for the 
generation of certain aspects of negative affect, such as ‘fear’ or ‘disgust’ that 
one experiences while in close proximity to an aversive stimulus. It is 
suggested that depression can be seen as an underactivation of the approach 
system and/or an overactivation of the withdrawal system. An overactivation 
of the withdrawal system is also proposed as being related to anxiety leading 
to inhibiting behavior and increase of arousal when confronted with an 
aversive stimulus.50;52 
C. The valence-arousal model was introduced by Heller and colleagues, and is an 
elaboration of the approach-withdrawal model. This model characterizes 
depression as Davidson does (i.e., decreased approach behavior and 
subsequent lower positive affect), but distinguished two subtypes of anxiety 
disorders, one associated with a dimension of anxious apprehension (e.g., 
obsessive compulsive disorder and generalized anxiety disorder) and another 
associated with a dimension of anxious arousal (e.g., panic disorder).50;53 This 
is somewhat consistent with the tripartite model that suggests that arousal is 
specific to certain anxiety disorders (like panic disorder) and that there may be 
other components that are unique to other anxiety disorders. The tripartite 
model, however, subsumes anxious apprehension under a general negative 
affect factor. Thus, a key distinction between the tripartite and Heller model 
is that anxious apprehension is viewed as factor separate from negative affect. 
The three models show a large conceptual overlap in their definition of the 
dimensions, e.g., all models differentiate between a positive and negative affect factor. 
However, the models slightly differ in the way that anxiety is taken into account as 
one or more separate dimensions. The approach-withdrawal system and the valence-
arousal model are frequently studied in relation to neural substrates by using the 
Positive and Negative Affects Scales (PANAS).54 One advantage of the tripartite 
model is the availability of a validated questionaire that assesses positive and negative 
affect, as well as anxious arousal, the so called Mood and Anxiety Symptom 
Questionnaire (MASQ).55-57 
 
The metabolic system  
Metabolic homeostasis is a crucial parameter of the adaptive stress response, since the 
activation of the HPA axis exerts potent transient effects on most of the metabolic 
pathways. Stressful conditions induce the rise of circulating cortisol, subsequently 
followed by increases of gluconeogenesis in the liver, lipolysis and protein degradation 
at multiple tissues (e.g., muscle, bone, skin). Consequently, most of the accessible 
stores of glucose, lipids, and amino acids are mobilized in order to be used as 
substrates that will supply the required energy to cope with the imposed stressor and 
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restore the internal milieu. The activated HPA axis antagonizes reproductive, growth 
and thyroid axis in order to temporally suspend every energy consuming process 
which at the moment is not essential for survival. The transient nature of the adaptive 
response renders its antagonized effects temporally beneficial for survival, rather that 
damaging.58 In contrast, chronic stress lead to detrimental metabolic complications as 
described beneath.  Figure 4 depicts the interactions between cortisol and parameters 
of the metabolic system. 
 
 
Figure 4. Interactions between cortisol and metabolic parameters 
+ denotes stimulation, and - denotes inhibition. 
 
Depression, anxiety and cardiovascular disease 
Patients with depression and anxiety disorders have a two to fourfold increased risk of 
developing cardiovascular disease (CVD).59-61 Several plausible mechanisms may 
explain the link between depression (and possibly also anxiety) and CVD. 
Pathophysiological alterations caused by depression and anxiety have been described, 
including impairment of platelet functions62;63 and a decreased heart rate variability as 
a consequence of an imbalance in the autonomic tone.64;65 Furthermore, immune 
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activation has been implicated in the pathogenesis of atherosclerosis and consequent 
CVD.66 Unhealthy lifestyles, such as smoking, low physical activity, and poor dietary 
habits, are well-known cardiac risk factors and have been found to be more common 
among depressed than nondepressed persons.67-69 Lastly, the link between depression 
and CVD may be caused by pharmacotherapeutic treatment. Antidepressants, in 
particular tricyclic antidepressants, may have a cardiotoxic effect.70-72 Additionally, 
depression has been hypothesized to be associated with the, so called, metabolic 
syndrome.73 The metabolic syndrome is described as a clustering of risk factors 
associated with CVD and diabetes. It includes at least three of the following 
conditions: abdominal obesity, high triglyceride levels, low high density lipoprotein 
(HDL) cholesterol, high blood pressure and high fasting glucose.74  
 
Cortisol and lipid metabolism 
Cortisol has important effects on the lipid metabolism and body composition. Cortisol 
activates lipoprotein lipase, the gatekeeper of lipid accumulation in adipocytes. 
Furthermore, cortisol in the presence of insulin inhibits the lipid mobilizing system. 
As a consequence, free fatty acids increase, and dyslipidaemia develops with elevated 
serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol and 
triglycerides, and decreased serum levels of HDL cholesterol. In the long term, 
cortisol excess also leads to an increase in visceral adiposity.75 Visceral adiposity refers 
to the distribution of fat around the abdomen (‘apple-shaped’), which is associated 
with an increased risk of CVD. The metabolic effects of cortisol are clearly 
demonstrated by the effects of synthetic glucocorticoids during anti-inflammatory and 
immunosuppressive therapy76 and in Cushing’s disease.77;78 The typical side effects of 
long-term exposure to high levels of cortisol or synthetic glucocorticoids are elevated 
serum levels of LDL cholesterol and triglycerides, lower HDL cholesterol, and 
elevated body-mass index (BMI) and waist-to-hip ratio (WHR).79;80;77;78 The few 
studies addressing these associations in patients with depression and anxiety disorders 
showed contradictory results. In a large cross-sectional survey of elderly depressed 
patients, high 24h urinary cortisol levels were associated with the metabolic syndrome, 
which includes high triglycerides and low HDL cholesterol.73 However, in another 
study higher salivary cortisol levels (measured at three time points during the day) 
were associated with lower LDL cholesterol levels in 41 overweight depressed patients 
(BMI > 25 kg/m2), but not in 37 patients of normal weight.81 Up to now, the 
association between lipids and cortisol levels in patients with anxiety disorders has not 
been studied. Investigating different aspects of HPA axis function (e.g., overall 
cortisol release, responsivity of the stress system) in relation to lipid metabolism might 
contribute to further disentanglement of this relationship. 
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The immune system 
Besides associations between HPA axis and lipid metabolism, there is also an 
interaction between the HPA axis and the innate and adaptive immune system. 
Proinflammatory cytokines, i.e., tumor necrosis factor α (TNF-α), interleukin 1 (IL-1) 
and interleukin 6 (IL-6), activate the HPA axis, leading to an increase in plasma 
cortisol levels. Cortisol, on its turn, inhibits the release of proinflammatory cytokines 
(Figure 5). One aspect of the innate inflammatory process is the acute phase response, 
with C-reactive protein (CRP) as a key pro-inflammatory marker. 
 
Acute phase response 
CRP is a proinflammatory acute-phase reactant, predominantly produced in the liver. 
The release of CRP is regulated by an inflammatory cascade of reactions, which 
involve, among others, proinflammatory cytokines.82;83 The main biological function 
of CRP is its ability to recognize pathogens and damaged cells of the host and to 
mediate their elimination by recruiting the complement system, which subsequently 
activates and attracts phagocytic cells.83 Due to its capability to bind to and modulate 
the function of mononuclear phagocytes, a process that is called opsonisation, CRP 
induces the release of the proinflammatory cytokines IL-1, IL-6, and TNF-α by these 
cells84 and, therefore, might indirectly stimulate cortisol release. Cortisol acts 
synergistically with IL-6 to enhance the release of CRP.85 On the other hand, cortisol 
is a potent endogenous anti-inflammatory agent with immunosuppressive effects. It 
has a strong capacity to suppress immune cell functions, particularly during the early 
development of the inflammatory response. It significantly decreases the production 
of cytokines and other mediators of inflammation (e.g., platelet activating factor, nitric 
oxide, prostanoids). However, not much is known yet about the direct pathways from 
CRP to cortisol release. We assume that a bidirectional relationship between CRP and 
cortisol plays an important role in maintaining the physiological homeostasis during 
the adaptive response to noxious stressors.86 Figure 5 depicts the Interactions between 
cortisol and parameters of the immune system). 
 
Thesis outline 
 
The main purpose of the present thesis is to investigate the associations between the 
HPA axis and phenotypic, metabolic and immune factors in patients with depression 
and anxiety disorders who were free of psychotropic medication. In the first two 
studies the HPA axis is used as a way to redefine the phenotype of patients suffering 
from depression and anxiety symptoms. The last two studies are on interactions 
between the HPA axis and the metabolic and immune system, focusing on, 
respectively, lipid metabolism and the acute-phase response. For all of this, we 
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assessed parameters involved in baseline HPA axis regulatory processes and used a 
neuroendocrine challenge design, the DEX/CRH test. Furthermore, we collected 
indices of lipid metabolism, adiposity, acute phase response and we determined the 
frequency of six well-characterized CRP polymorphisms. The study population 
consists of outpatients with depressive and/or anxiety disorders and healthy controls. 
By means of these studies, we hope to reach a better understanding of the correlates 
and determinants of the complex HPA system in depression and anxiety disorders.  
 
 
Figure 5. Interactions between proinflammatory cytokines interleukin-1 (IL-1), tumor necrosis factor α 
(TNF-α), interleukin-6 (IL-6) and cortisol and C-reactive protein (CRP) 
+ denotes stimulation, and - denotes inhibition. 
 
As a preface to the empirical studies of this thesis, we wrote an introductory article on 
the need for alternative ways of phenotyping of mood, anxiety and somatoform 
disorders in biological research (chapter 2). 
In the first empirical study, we hypothesized that psychiatric comorbidity might be 
an explaining factor for the heterogeneous outcome of the DEX/CRH studies in 
patients with depression. The attention for psychiatric comorbidity, although it is a 
frequently occurring phenomenon, is remarkably limited. Furthermore, comorbidity 
was often not addressed as explaining factor for the broad range in cortisol and 
ACTH values within and between DEX/CRH studies. We investigated whether 
psychiatric comorbidity affects the responsivity to the DEX/CRH test in patients with 
depression, who were free of psychotropic medication (chapter 3). 
In the second empirical study a dimensional model was used in the search for 
underlying HPA axis dysfunctions of the clinical phenotype.  For this, we choose the 
tripartite model of anxiety and depression, because it is broadly accepted in adult 
psychiatry87-89 and because a validated questionaire exists to assess the dimensions is 
available.55 Continuous psychological dimensions selected for their predictiveness of 
HPA-dysfunctions were proposed to be the advantageous way in reaching an 
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understanding of the biological causations in depression and anxiety, and may be 
complementary to DSM-IV diagnoses when doing neuroendocrine research (chapter 
4).  
Next, we investigated the interaction between the HPA axis and lipid metabolism 
in depression and anxiety disorders. The effects of cortisol on lipid metabolism (and 
adiposity) make HPA axis dysfunctions one of the possible mediator of the 
association between depression and anxiety disorders and CVD.73 We studied two 
aspects of the HPA axis function (i.e., basal cortisol release over the day, and circadian 
cortisol variability as indicator of the responsivity of the stress system) in relation to 
lipid metabolism and adiposity (chapter 5). 
In the last study, associations were explored between CRP haplotypes with plasma 
CRP levels and basal salivary cortisol in a genetic association study. Six well-
characterized CRP polymorphisms that are known to influence plasma CRP levels 
were used in order to explore the relationship between CRP levels and salivary cortisol 
levels over the day (chapter 6).  
 In chapter 7 the results of the different studies and the interface between them 
will be discussed. The final part of this chapter includes some future perspectives.  
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Abstract 
 
Variation in psychiatric symptomatology is continuous and does not coalesce into 
fairly well defined categorical DSM-IV clusters. As a consequence, DSM-IV fails to 
meaningfully integrate information generated by neuroendocrine research. Continuous 
psychological dimensions selected for their predictiveness with respect to 
endophenotypes, as biological intermediate factors, are proposed to be the best way in 
reaching an understanding of the causations in mood, anxiety and somatoform 
disorders. 
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Introduction 
 
Nowadays, psychopathology is mostly described in terms of diagnostic categories 
according to the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV). 
An important advantage of this system is that it yields reliable diagnoses, especially 
with respect to classical psychiatric disorders like depression and panic disorder, which 
are subsumed under axis I in the DSM-IV. However, the validity is open to debate. 
Firstly, the majority of patients shows a complex presentation of a wide range of 
psychiatric symptoms, often leading to more than one axis I diagnoses, 
simultaneously. Therefore, the face validity of the categorical approach of the DSM-
IV has been questioned. Secondly, in general, each DSM-IV diagnosis requires the 
presence of a minimum number of symptoms out of a list of symptoms characterizing 
the disorder. However, the threshold level is mostly chosen arbitrarily, but above the 
mean number of symptoms found in the general population. As a consequence, the 
DSM-IV excludes a large group of persons with below-threshold psychopathology. 
Thirdly, as a diagnosis does not require the presence of all symptoms listed for the 
diagnosis, patients with the same DSM-IV disorder may differ greatly with respect to 
their symptoms. For example, two depressive patients may suffer from opposite 
symptoms, e.g. hyposomnia versus hypersomnia. By using DSM-IV classification, this 
clinical heterogeneity is not specified or adequately described. Fourthly, no close 
relationship between the DSM-IV axis I diagnoses and biological markers has been 
found. For instance, notwithstanding the indications that stress plays an important 
role in the development of mood, anxiety and somatoform (MAS) disorders, only in 
about half of the patients hypothalamic-pituitary-adrenal (HPA) axis dysregulations 
are found. Furthermore, often opposite findings are found within one diagnostic 
entity, e.g. hyper- and hypocortisolism in respectively melancholic and atypical 
depression.1;2  
Does this imply that we look at the wrong biological markers or do we make the 
wrong groupings of the phenotype? In this article we explore the latter possibility and 
propose the need for alternative ways of phenotyping of MAS disorders in biological 
research. 
 
Phenotype: Diagnosing MAS disorders 
 
In 1990, Van Praag proposed a new diagnostic approach, named functionalization and 
verticalization. Functionalization comprises converting categorical diagnoses into the 
psychic dysfunctions underlying the psychopathological symptoms. This enables the 
verticalization, by which is meant connecting the psychic dysfunction with the 
underlying neurobiological substratum. To do so, a sequential analysis is required, i.e. 
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determination of the sequence of appearance of symptoms, because it is hypothesized 
that the first symptoms, called front runners by Van Praag, carry a primary character 
with respect to neuroendocrine dysfunctions. Examples are the associations between 
serotonergic dysfunctions and disturbances in anxiety, aggression regulation and 
impulse control, and between dopaminergic dysfunctions and disturbances in 
motoricity.3-5 
Unfortunately, for many types of psychic dysfunctions the front runners are 
unknown or difficult to determine. Instead of the front runners, the dimensions 
underlying the psychic dysfunctions may also be an appropriate link between 
psychopathology and neuroendocrine dysfunctions. Dimensional models, in contrast 
to functionalization and verticalization, do not require a sequentional analysis of 
psychic dysfunctions, because it is hypothesized that for each patient assessment on all 
dimensions that cover the psychopathology is sufficient for meaningfull integration 
with the information generated by neuroendocrine research. Several dimensional 
models have been proposed for assessing mood and anxiety disorders, such as the 
tripartite model, approach-withdrawal model, and valence-arousal model. All these 
models posit that mood and anxiety disorders share a common distress dimension, 
but they also can be distinguished from each other by particular characteristics.6 A 
shortcoming of these models is that they still use the DSM-IV classification as frame 
of reference by proposing dimensions with assumed predictiveness for DSM-IV 
diagnoses instead of looking for dimensions with a high concordance with biological 
markers, the so called endophenotypes. The development of a new dimensional 
model, independent of DSM-IV diagnoses, and external validated with 
endophenotypes, is needed. 
 
Endophenotype: The crucial link in between 
 
An endophenotype is a biological marker of a phenotype closer to relevant gene 
action than the phenotype itself. Endophenotypes should be continuously quantifiable 
and predict disorders probabilistically. In the case of psychopathology, 
endophenotypes may be neurophysiological, biochemical, endocrinological, 
neuroanatomical, cognitive, or neuropsychological in nature. As MAS disorders are 
linked to stress, it is hypothesized that dysfunction of one of the important stress 
systems, the HPA-axis, is an endophenotype of these disorders.  
Indeed some indications have been found that HPA-axis dysfunction is an 
endophenotype of MAS disorders diagnosed according to the DSM-IV. About half of 
the patients with a major depressive disorder show a hyperactivity of the HPA-axis. 
Studies of anxiety disorders revealed less robust HPA-axis dysregulations. Some, but 
not all patients with posttraumatic stress disorders, show hypocortisolism. 
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Hypocortisolims has been reported in 20-25% of patients with somatoform 
disorders.7-9 Given the questionable validity of diagnoses based on the DSM-IV, no 
large correlations between diagnoses of this type and biological markers are to be 
expected.  
A few studies have examined HPA-axis activity in relation to psychic dysfunctions, 
instead of DSM-IV classification. Hyperactivity of HPA-axis is considered to play an 
important role for individual symptoms, such as enhanced anxiety, decreased 
responsiveness to the environment, decreased diurnal variation, disturbed sleep, 
altered psychomotor functions, decreased appetite and libido, and impaired cognition. 
Reduced HPA-axis activity, mediated by an enhanced negative feedback, is associated 
with symptoms, such as hypersomnia, hyperphagia, lethargy, and fatigue.10-12 
The relationship between dimensional models and HPA-axis activity has, so far 
known, never been studied.   
 
A model to study dimensions of mood, anxiety and somatisation and HPA-axis 
functioning 
 
We propose that the development of a dimensional model that covers the 
symptomatology of all three MAS disorders is needed to reach more insight in its 
biological substrate. By using psychological questionnaires that assess a broad 
spectrum of symptoms, one can look for underlying dimensions that adequately and 
precisely describe MAS psychopathology. Dimensions don’t need to have predictive 
value for separate DSM-IV diagnoses, but should be externally validated with 
biological markers, such as HPA-axis function. Basal HPA-axis activity can be 
measured by assessment of the cortisol diurnal pattern. HPA-axis reactivity can be 
examined with challenge tests like the combined dexamethasone/corticotrophin-
releasing hormone (CRH) challenge test, which proved to be a sensitive measure 
(above 80%) in differentiating depressive patients from healthy controls.13 It is used to 
examine HPA reactivity under the condition of suppressed glucocorticoid feedback as 
a reflection of the sensibility and responsivity of the pituitary. We hypothesize that 
combining these phenotypic and endophenotypic data will lead to more clarity about 
psychopathological processes in MAS disorders.  
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Abstract 
 
Objective: The outcome of the dexamethasone/corticotropin-releasing-hormone 
(DEX/CRH) test in depressed patients is heterogeneous. The present study 
investigated whether comorbidity of anxiety or somatoform disorders might be an 
explaining factor for this finding. 
 
Methods: The DEX/CRH test was administered in 36 pure major depressive 
outpatients, 18 major depressive outpatients with a comorbid anxiety and/or 
somatoform disorder, and 43 healthy controls. Patients were free of psychotropic 
medication. Group differences in responsivity to the DEX/CRH test were analysed. 
 
Results: Depressive patients with comorbidity showed a significant lower cortisol 
response compared to pure depressive patients (p=.04) and controls (p=.003). Group 
differences between MDD patients with and without comorbidity in cortisol 
responses disappeared after adjustment for post-DEX cortisol concentrations (p=.34).  
 
Conclusions: An enhanced suppression of cortisol to 1.5 mg DEX is present in a 
subgroup of depressed patients with psychiatric comorbidity. Distinct hypothalamic-
pituitary-adrenal (HPA) axis dysfunctions are revealed when comorbidity is taken into 
account.  
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Introduction 
 
Investigating the function of the hypothalamic-pituitary-adrenal (HPA) axis, 
hyperresponsiveness to the dexamethasone/corticotropin-releasing-hormone test 
(DEX/CRH test) is a frequent finding in patients with major depressive disorder 
(MDD).1-8 Yet, some studies found no change9-12 or even hyporesponsiveness 13. 
Actually, cortisol responses to the DEX/CRH test showed a broad range within and 
between studies. For instance, mean peak plasma cortisol values in depressed patients 
ranged from about 150 nmol/l13 to about 300 nmol/l.14  
There are several explanations for these heterogeneous findings. Firstly, depression 
severity of the patients differed widely between studies, ranging from a mean HDRS-
score of 1710 to about 28.3;6 Secondly, patients on medication were often included, 
whereas antidepressive medication may affect HPA-axis function. One study found 
that antidepressants restored HPA-axis function, and that this preceded symptom 
resolution,7 although this was not found in another study.15 Thirdly, heterogeneous 
findings may also be explained by the inclusion of patients with bipolar depression in 
some studies.4;6;8 
We hypothesize that psychiatric comorbidity might be an explaining factor for the 
heterogeneous outcome of the DEX/CRH studies. The attention for psychiatric 
comorbidity, although it is a frequently occurring phenomenon, is remarkably 
limited.10;16;17 Most studies did not report on comorbid psychiatric disorders,4;8 while 
another study mentioned comorbidity, but did not address it in the statistical 
analyses.12 In the present study comorbidity was limited to anxiety and somatoform 
disorders, because they frequently co-occur with major depression.  
In the present study we investigated whether psychiatric comorbidity and severity 
of psychopathology affect the responsivity to the DEX/CRH test in 50 patients with 
MDD, who were free of psychotropic medication. Forty-three healthy controls were 
included as a reference group. 
 
Methods 
 
Participants 
Fifty patients suffering from MDD were recruited from the outpatient department of 
the mental health center Rivierduinen in Leiden, the Netherlands. All patients met the 
criteria of a MDD according to the DSM-IV criteria in the Dutch version of the Mini 
International Neuropsychiatric Interview Plus 5.0.0-R (MINI-Plus).18;19 Comorbidity, 
assessed with MINI-Plus, was allowed for anxiety disorders (i.e., panic disorder, social 
anxiety disorder, obsessive compulsive disorder, generalized anxiety disorder or 
posttraumatic stress disorders) and undifferentiated somatoform disorders, but other 
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axis I disorders were a reason for exclusion. The MINI-Plus was administered by 
trained interviewers. Patients were divided into two groups, one containing 32 
depressed patients without comorbidity (MDD/pure group) and 18 depressed patients 
with a comorbid anxiety and/or somatoform disorder (MDD/com group). Forty-
three healthy controls were recruited by advertisement in local news papers asking for 
healthy persons willing to participate in a study on the biological stress system in 
relation to depression and anxiety. Around 55 persons responded to the 
advertisements. Controls were included if they had no present or lifetime history of 
any axis I psychiatric disorder as assessed by the MINI-Plus and neither reported any 
traumatic experience in history.  Patient groups and control group were comparable 
for age (F2,88= 1.7; p=0.20) and gender (χ22,88= 1.1; p=0.57). Exclusion criteria for 
patients and controls were a history of neurological or endocrine diseases or other 
serious unstable medical conditions. Furthermore, patients and controls with 
substance or alcohol abuse, as well as pregnant or breast feeding women and 
premenopausal women with ovarectomy were excluded. None of the controls used 
any psychotropic medication. Patients using psychotropic medication with exception 
of a low dose of a benzodiazepine (equivalent to 30 mg oxazepam daily) were also 
excluded. If psychotropic medication was used within the last 14 days (for fluoxetine 
six weeks) patients were excluded. Patients were included on admission before the 
start of (pharmaco)therapy, or during treatment when medication was tapered in case 
of clinical ineffectiveness before the switch to another medication. Additionally, 
patients and controls using corticosteroids, antidiabetics, estrogens, (anti)thyroid 
hormone, or herbal medication (e.g., Valerian, St. Johns Wort) were excluded. All 
participants had a routine physical examination and laboratory blood tests. Prior to 
participation, written informed consent was obtained from all participants. The study 
was approved by the local ethics committee of the Leiden University Medical Center.   
 
Dexamethasone/CRH test 
The DEX/CRH test was performed according to the protocol developed by Heuser 
(Heuser et al., 1994). Participants took one tablet of DEX of 1.5 mg orally at 23:00h 
on the evening before neuroendocrine testing. They attended the research unit of the 
hospital the following day at 12:30h and had a light lunch upon arrival. At 13:45h a 
cannule was placed in the antecubital fossa. Participants were fasting throughout the 
experiment, remained semi-supine and non-sleeping. Human CRH (100 μg) (Ferring 
Hoofddorp, The Netherlands) was administered via the cannule at 15:02h. Blood 
samples for assessment of cortisol and adrenocorticotropic hormone (ACTH) were 
collected at 15:00h (pre-CRH), 15:30h, 15:45h, 16:00h, 16:15h, 16:30h and 16:45h. 
Blood samples were obtained in EDTA tubes (Sarstedt) on ice and were stored 
directly at -70 oC before assessment. The determination of cortisol in plasma was 
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performed with a competitive electrochemiluminescence immunoassay (ECLIA) using 
a Modular Analytics E170 immunoassay analyzer from Roche Diagnostics 
(Mannheim, Germany).  The detection limit for cortisol was 2.0 nmol/l and the intra- 
and inter-assay variability coefficients in the measuring range were less than 10%. The 
determination of ACTH was performed with a solid-phase, two-site sequential 
chemiluminescent immunometric assay using an Immulite 2500 immunoassay analyzer 
from DPC (Los Angeles, USA). The detection limit for ACTH was 1.1 pmol/l and 
the total precision in the measuring range was about 5%.  
 
Measure of severity of psychopathology 
Patients completed the Dutch translation of the Brief Symptom Inventory (BSI), a 
shortened version of the Symptom Checklist (SCL-90), that is used to measure 
psychological complaints or symptoms.20 The total BSI-score generates an overall 
measure of psychopathological symptom severity. Internal consistency of the BSI is 
very good (Cronbachs α=0.96), and validity is sufficient.20 
The Short Comprehensive Psychopathology Rating Scale (sCPRS)21 is a semi-
structured diagnostic interview, developed to assess psychiatric symptoms and most 
often used for screening purposes. Two indices have been derived from the shortened 
version (25 items) of the CPRS, the Brief Anxiety Scale (BAS)22 to measure anxiety 
severity and the Montgomery Åsberg Depression Rating Scale (MADRS)23 to measure 
depression severity. 
 
Statistical analyses 
Group differences for clinical characteristics were assessed by independent t-tests and 
one-way analysis of variance (ANOVA) for continuous variables, and 2-tests for 
categorical variables. 
As indices of DEX suppression we used the 15:00h plasma concentrations of 
cortisol and ACTH after oral DEX intake, but before CRH administration, reported 
in analyses as BASELINE. For determination of the hormonal responses to the 
additional CRH administration in DEX-pretreated participants, the total area under 
the curve (AUC) was calculated with the trapezoid formula.24 Oneway ANOVA was 
used to investigate group differences in BASELINE and AUC measures. Groupwise 
comparisons were adjusted for multiple testing using least significant difference (LSD) 
correction. Log-transformed values of cortisol and ACTH measures were used, 
because data were positively skewed. Analyses were adjusted for age, gender, and 
smoking status. 
Additional exploration of the data was undertaken to investigate the impact of 
severity of psychopathology on the responsivity to the DEX/CRH test in patients. 
The total BSI-score was used as global index of psychiatric disease severity. 
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Furthermore, the influence of post-DEX suppression of cortisol on the responsivity 
to the additional CRH administration was examined. One-way ANOVA was repeated 
with AUC as dependent variable and the BSI total-score and BASELINE added, 
respectively, as covariates. Analyses were performed using Statistical Package or the 
Social Science version 16.0 (SPSS 16.0). Analyses were two-tailed with the level of 
significance set at .05. 
 
Table 1. Clinical characteristics of MMD/pure group, MDD/com group, and control group 
 MDD/pure 
group 
(n=32) 
MDD/com 
group  
(n=18) 
Control 
group 
(n=41) 
Test,  
p-value 
Age 33.8  11.2 28.4  8.2 33.9  12.3 F2,88=1.7, 
p=0.20 
Gender (% females) 18 (56.3%) 11 (61.1%) 28 (68.3%) χ22,88=1.1, 
p=0.57 
Smoking (% smokers) 18 (56.3%) 10 (55.6%) 4 (9.8%) χ22,88=21.1, 
p<0.01 
BMI (kg/m2 24.4  4.1 25.8  9.1 24.4  3.8 F2,88=0.46, 
p=0.64 
Age of onset MDD 23.9  11.3 21.5  7.1  t1,48=0.82, 
p=0.42 
Recurrent MDD (% 
patients) 
23 (71.7%) 10 (55.6%)  χ21,48=1.4, 
p=0.24 
 Panic disorder  4   
 Social anxiety disorder  5   
 Obessive-compulsive 
disorder 
 1   
 Post-traumatic stress 
disorder 
 6   
 Undifferentiated 
somatoform disorder 
 3   
Total BSI score 1.5  .64 1.7  .53  t1,48=1.1, 
p=0.30 
MADRS score 23.1  6.8 24.1  6.2  t1,48=0.49, 
p=0.63 
BAS score 15.0  5.5 18.6  6.2  t1,48=2.1, 
p=0.047 
Data are presented as means  standard deviation (SD) or n (percentage).  
BAS = Brief Anxiety Scale; BMI = body-mass index; BSI = Brief Symptom Inventory; MADRS = 
Montgomery Åsberg Depression Rating Scale. 
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Results 
 
Clinical characteristics 
Clinical characteristics are presented in table 1. Patient groups and controls did not 
differ significantly for gender, age, and body-mass index (BMI). Significant group 
differences were found for smoking status, with patients smoking more frequently 
compared to controls. Patient groups did not differ in age of onset of MDD or 
recurrence of episodes of MDD. Furthermore, patient groups did not differ for the 
total BSI-scores, and MADRS, but the MDD/com group showed a significantly 
higher score on the BAS compared with the MDD/pure group.  
 
Cortisol and ACTH responses to the DEX/CRH test 
Figure 1 shows the cortisol and ACTH responses to the DEX/CRH test. One-way 
ANOVA revealed a non-significant group difference for BASELINEcortisol (F2,88=2.3, 
p=0.11). Post-hoc tests, adjusted for multiple comparisons, showed a lower cortisol 
concentration at 15:00h for the MDD/com group as compared to the MDD/pure 
group (p=0.04). Regarding the cortisol response to the additional CRH administration, 
one-way ANOVA revealed a significant main effect of group for AUCcortisol (F2,88=5.0, 
p=0.01). In post-hoc tests, the MDD/com group showed a significantly lower 
AUCcortisol as compared to the MDD/pure group (p=0.03) and controls (p=0.002). 
The MDD/pure group and controls did not differ in their cortisol response to the 
DEX/CRH test (p=0.32).  
15:00h 15:30h 15:45h 16:00h 16:15h 16:30h 16:45h
Pl
as
m
a 
co
rt
is
ol
 ( 
m
ol
/L
)
14
20
30
40
50
70
100
140
MDD/pure group
MDD/com group
healthy controls
15:00h 15:30h 15:45h 16:00h 16:15h 16:30h 16:45h
Pl
as
m
a 
A
C
TH
 (n
g/
L)
4
5
6
7
8
10
12
MDD/pure group
MDD/com group
healthy controls
Figure 1. Cortisol and ACTH response to the DEX/CRH test 
Data are graphical presented as means with bars representing SE; patients are subdivided according to DSM-
IV categories. DEX 1.5 mg was orally taken at 23:00h on the evening before. CRH 100 μg was 
administered at 15:02h. Cortisol and ACTH levels are depicted on a logarithmic scale. 
 
No group differences were found for BASELINEACTH (F2,88=1.4, p=0.25). Regarding 
the ACTH response to the additional CRH administration, one-way ANOVA revealed 
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a trend towards significance for the main effect of group for AUCACTH (F2,88=2.8, 
p=0.07). Post hoc tests revealed that this trend could be attributed to a lower ACTH 
response for the MDD/com group as compared to controls (p=0.02), whereas no 
group differences in AUCACTH were found for the other contrasts. 
 Subsequently, all analyses were adjusted for the effect of age, gender, and smoking 
status. None of the main findings were significantly affected by these covariates (data 
not shown). 
 
Comparisons between the MDD/pure group and MDD/com group 
Additional analyses were performed on the differences in cortisol and ACTH 
response to the DEX/CRH test between the MDD/pure group and MDD/com 
group. One-way ANOVA was performed with, subsequentially, BASELINEcortisol and 
AUCcortisol as dependent variables and with age, gender, and smoking status added as 
covariates (model 1). None of these covariates showed to be significantly associated 
with BASELINEcortisol or AUCcortisol and group differences remained significant or 
changed to a trend towards significance with lower cortisol levels in the MDD/com 
group compared to the MDD/pure group (respectively, p=0.06, p=0.03). In a next 
step, the BSI total-score was added as a covariate to the analysis, to investigate 
whether severity of psychopathology could explain the differences in cortisol 
responsivity to CRH administration (model 2). The BSI total-score was not 
significantly associated with BASELINEcortisol and AUCcortisol, and the main group 
effect remained significant or changed to a trend towards significance (respectively, 
p=0.06, p=0.02). The same findings were found after adjustment for either the 
MADRS or BAS (data not shown). In a last step (model 3) we repeated the analysis 
with AUCcortisol and adjusted for BASELINEcortisol  to examine whether the differences 
in post-DEX suppression of cortisol at 15:00h (pre-CRH) could explain the 
differences in cortisol responsivity to CRH administration (model 3). BASELINEcortisol 
was significantly associated with the AUCcortisol (p<0.001) and the main group effect 
was no longer significant (p=0.24) (table 2).  
 Same analyses were done with, subsequentially, BASELINEACTH and AUCACTH as 
dependent variables. No significant group differences were found between the 
MDD/pure group and the MDD/com group for all models (table 2).  
In sensitivity analyses, patients with PTSD and patients with somatoform disorders 
were omitted to explore whether the lower cortisol responses to the DEX/CRH test 
could be ascribed to the somatoform disorders or post-traumatic stress disorder 
patients within the MDD/com group. After omitting patients with PTSD (n=6), 
group differences remained significant for BASELINEcortisol and AUCcortisol 
(respectively, F1,42=5.6, p=0.02, F=1,42=4.2, p=0.046). When AUCcortisol was adjusted 
for BASELINEcortisol (model 3), the main group effect was no longer significant 
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(F1,38=0.18, p=0.68). In reanalyses when excluding patients with somatoform 
disorders (n=3), group differences remained also significant for BASELINEcortisol and 
AUCcortisol (respectively, F1,46=4.3, p=0.04, F=1,46=5.1, p=0.03).  When AUCcortisol was 
adjusted for BASELINEcortisol (model 3), the main group effect was again no longer 
significant (F1,42=1.1, p=0.31).  
 
Table 2. BASELINE and AUC of cortisol and ACTH as indices of the responsivity to the 
DEX/CRH test in MDD/pure group, MDD/com group 
 MDD/pure group 
(n=32) 
MDD/com group 
(n=18) 
Test, p-value 
BASELINEcortisol 
(nmol/L)a 
30.4 (22.8 –  40.7) 17.2 (11.7 - 25.4) F1,48=5.6, p=0.02 
 Model 1 29.4 (22.0 –  39.4) 18.3 (12.3 –  27.1) F1,45=3.7, p=0.06 
 Model 2 29.6 (22.0 –  39.8) 18.1 (12.1 –  26.9) F1,44=3.9, p=0.06 
AUCcortisol 
(nmol/L/h)a 
110.5 (79.2 – 154.3) 57.5 (36.8 – 89.6) F1,48=6.4, p=0.02 
 Model 1 107.4 (77.0 – 149.9) 60.5 (38.6 – 94.7) F1,45=4.8, p=0.03 
 Model 2 108.8 (77.9 – 152.1) 59.1 (37.6 – 92.8) F1,44=5.4, p=0.02 
 Model 3 94.3 (73.1 – 121.7) 76.2 (53.9 – 107.8) F1,44=1.4, p=0.24 
BASELINEACTH 
(ng/L)a 
5.1 (4.6 – 5.6) 4.6 (4.0 – 5.3) F1,48=1.3, p=0.25 
 Model 1 5.1 (4.6 –  5.6) 4.7 (4.1 –  5.4) F1,45=.87, p=0.36 
 Model 2 5.1 (4.6 –  5.6) 4.6 (4.0 –  5.3) F1,44=1.5, p=0.22 
AUCACTH 
(ng/L/h)a 
14.1 (11.8 – 16.9) 11.3 (8.9 – 14.3) F1,48=2.3, p=0.14 
 Model 1 13.9 (11.6 – 16.7) 11.6 (9.1 – 14.8) F1,45=1.5, p=0.24 
 Model 2 14.0 (11.7 – 16.8) 11.5 (9.0 – 14.6) F1,44=1.8, p=0.19 
 Model 3 13.6 (11.6 – 16.0) 12.1 (9.7 – 15.1) F1,44=.74, p=0.39 
Data are presented as estimated means with 95% Confidence Interval (CI) within groups. 
P-values of one-way ANOVAs are presented.  
Model 1: adjusted for age, gender, and smoking (yes/no); Model 2: adjusted for age, gender, smoking, and 
overall severity (BSI total-score); Model 3: adjusted for age, gender, smoking and BASELINE. 
a log- transformed values were used in statistical analyses because data were positively skewed. 
 
Discussion 
 
In the present study, we investigated whether psychiatric comorbidity and severity of 
psychopathology affect the responsivity to the DEX/CRH test in depressed patients 
who were free of psychotropic medication. Our results indicate that comorbidity in 
depressed patients leads to an enhanced post-DEX suppression of cortisol, and 
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consequently to a lower cortisol response to CRH administration. After adjustment 
for post-DEX cortisol concentrations, no difference in cortisol response to the 
DEX/CRH test was found between depressed patient with and without psychiatric 
comorbidity. Severity of psychopathology was not associated with the responsivity to 
the DEX/CRH test. 
Our finding of lower cortisol responses to the DEX/CRH in depressed patients 
with comorbidity as compared to controls is in line with findings of a previous study13. 
In this study, depressive female patients on long-term sick leave showed attenuated 
cortisol responses to the DEX/CRH test. However, differences in post-DEX cortisol 
concentrations were not examined in their study and it remained unclear whether 
comorbidity might have been a contributing factor. In most previous studies, a higher 
percentage of non-suppression of post-DEX cortisol before CRH administration was 
found in depressive patients.1;2;5;7;8;25;26 In some studies using the DEX suppression 
test also an enhanced post-DEX suppression of cortisol levels was found. Specifically 
in MDD patients with a history of traumatic life events and/or patients with post-
traumatic stress disorder.27-29 Our finding of an enhanced DEX suppression of 
cortisol when using the DEX/CRH test in depressed patients with psychiatric 
comorbidity is therefore, to the best of our knowledge, an important new finding, 
which needs to be replicated. It seems unlikely that any individual psychiatric 
comorbid disorder explains our finding, as previous studies on pure anxiety disorders 
have reported no enhanced post-DEX cortisol suppressive effects.3;7;30 Sensitivity 
analyses also indicated that individual psychiatric comorbid disorders, specifically 
somatoform disorders and PTSD, did not influence our findings. Furthermore, it is 
unlikely that clinical variables, such as age of onset of MDD or recurrence of episodes 
of MDD, could explain our finding of the enhanced DEX suppression, because 
patient groups did not significantly differ on these clinical aspects. Lastly, the use of 
psychotropic medication could not have influenced the DEX suppression, because we 
included medication-free patients with a mild to moderate depression (mean MADRS 
score of 23.5) on admission before the start of (pharmaco)therapy, or during 
treatment when medication was tapered in case of clinical ineffectiveness before the 
switch to other medication. 
One of the mechanisms that could explain the enhanced suppression to DEX is 
enhanced central glucocorticoid receptor sensitivity. DEX, a synthetic glucocorticoid, 
mimics the negative feedback effect of cortisol; it binds with high affinity to the 
glucocorticoid receptor in the pituitary gland, inhibiting peripheral release of cortisol. 
The extent to which cortisol release is inhibited after DEX intake indicates central 
feedback sensitivity.31;32 The lower cortisol concentrations after DEX intake in our 
sample of MDD patients with comorbidity indicate increased negative feedback 
sensitivity in this group of depressed patients.  
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The influence of comorbidity on HPA-axis regulation in depressed patients has 
rarely been studied. Some studies used a psychological paradigm, the Trier Social 
Stress Test (TSST), to investigate the HPA-axis. Purely depressed patients showed no 
differences in cortisol and ACTH response compared to controls for the TSST. In 
case of comorbid anxiety disorders an exaggerated ACTH response was found.33;34 
The TSST examines the psychological stress response using a psychological stimulus, 
while the DEX/CRH test examines the neuroendocrine stress response using a 
pharmacological stimulus. This basal difference makes it hard to compare their results. 
Some methodological limitations on this study should be mentioned. Firstly, the 
sample size was relatively small, particularly of the MDD/com group. Secondly, we 
found relatively high cortisol and ACTH values in our control group with a mean 
peak cortisol value of 212 nmol. In previous studies mean peak cortisol values in 
healthy controls ranged from about 70 nmol/l3;12 to about 220 nmol/l.13 Our relative 
high cortisol values might be related to a bias in the recruitment of the controls, e.g., 
mostly non-working participants responded to our advertisements, which might be a 
distinct population within society. Nevertheless, this has no implications for the 
presented differences between the MDD/pure group and MDD/com group on HPA-
axis dysfunctions. Thirdly, we did not collect further clinical data that might have 
confounded or mediated the associations, like the duration of the current MDD 
episode or comorbid disorder, the presence of a family history of psychiatric 
disorders, and specific symptoms such as sleep disturbances. Other clinical variables 
that were assessed (i.e., age of onset and recurrence of MDD) did not significantly 
differ between patient groups. Lastly, we did not consider effects of genotype, 
personality traits, and early life trauma, all of which might impact the DEX/CRH test 
results. 
We found that an enhanced suppression of cortisol to 1.5 mg DEX is present in a 
subgroup of depressed patients with comorbid anxiety and/or somatoform disorders. 
However, no differences in cortisol responsivity to CRH administration were found 
after adjustment for the post-DEX cortisol concentration, suggesting that a stronger 
negative feedback to DEX explains the difference.  
Our finding of an enhanced DEX suppression of cortisol when using the 
DEX/CRH test in depressed patients with psychiatric comorbidity is of importance, 
because it underlines that comorbidity should be taken into account when interpreting 
the results of studies on the HPA-axis functioning in depressive patients. Replication 
of this study is needed to validate our results. Furthermore, it remains to be elucidated 
why psychiatric comorbidity in patients with MDD leads to an enhanced DEX-
suppression of cortisol. 
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Abstract 
 
Objective: The Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV 
classification may fail to adequately distinguish neuroendocrine factors involved in the 
etiology of depressive and anxiety disorders. Continuous phenotypic dimensions may 
correlate better with underlying neuroendocrine dysregulations.  
 
Methods: We compared the categorical DSM-IV diagnoses with a dimensional 
approach in the same group of outpatients with depressive (n=36), anxiety (n=18), and 
comorbid depressive and anxiety (n=19) disorders, who were free of psychotropic 
medication, and in 36 healthy controls. The Mood and Anxiety Symptom 
Questionnaire (MASQ) was used to measure the three dimensions of the tripartite 
model, i.e., anhedonic depression, anxious arousal, and general distress. The salivary 
cortisol awakening response (CAR) (0, 30, 45, and 60 min after awakening), and 
diurnal cortisol decline (11:00h, 15:00h, 19:00h, and 23:00h) were analysed for linear 
and non-linear associations.  
 
Results: The CAR showed statistically significant non-linear relationships with two 
MASQ dimensions, i.e., anhedonic depression and general distress, but no differences 
between DSM-IV categories. The diurnal cortisol decline was linearly related to the 
MASQ dimensions anhedonic depression and general distress and significantly higher 
AUCdiurnal levels and a steeper slope were found in depressive patients compared to 
controls using DSM-IV categories.  
 
Conclusion: The present study shows that linear and non-linear associations with 
salivary cortisol are detected when using phenotypic dimensions and may be 
complementary to phenotypic DSM-IV categories when doing neuroendocrine 
research.  
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Introduction 
 
Stress and stress vulnerability have been hypothesized to play an etiological role in 
depressive and anxiety disorders, marked by a dysfunction of the hypothalamic-
pituitary-adrenal (HPA) axis.1-3 Previous studies show inconsistent and contradictory 
findings regarding these HPA dysfunctions in relation to depression and anxiety. 
Elevated plasma cortisol levels were found in patients with depressive disorder,4;5 but 
decreased or no alterations of plasma cortisol levels were found in chronic depressed 
patients and in a subgroup of atypical depressed patients with an early onset and/or 
chronic form of depression.6;7 Studies in outpatients and community populations have 
provided limited evidence of HPA axis dysfunctions in depression.8-10 Furthermore, in 
older depressive patients, associations were found with hypercortisolism as well as 
with hypocortisolism, indicating the possibility of a non-linear, U-shaped association 
between depression and cortisol.11;12 Most studies on primary anxiety disorders 
suggest that basal cortisol and ACTH concentrations are unaltered. In challenge 
conditions, higher as well as lower HPA axis responsiveness was found in patients 
with anxiety disorders as compared to healthy controls.4;6;7;13-17 
The lack of consistent findings regarding the HPA axis dysfunction in patients 
with depressive and anxiety disorders could be explained, at least in part, by the 
limited specificity of the categorical DSM-IV diagnoses. This may be due to the 
overlap of DSM-IV diagnoses by sharing criteria. Furthermore, the presence of non-
linear associations between cortisol measures and psychopathology might have 
contributed to the inconsistent findings.11;12  
A dimensional approach may be an alternative in the search for underlying 
biological dysfunctions of the clinical phenotype. For the present study, we chose the 
tripartite model of anxiety and depression, because it is broadly accepted in adult 
psychiatry.18-20 Clark and Watson’s tripartite model is designed to handle the high 
comorbidity rates of depressive and anxiety disorders21 through taking account of 
both overlapping and distinct features of anxiety and depression. Low positive affect 
(also called the ‘anhedonic depression’ dimension) is thought to be specific for 
depression, whereas somatic arousal (also called the ‘anxious arousal’ dimension) is 
more specific for anxiety. High negative affect (also called the ‘general distress’ 
dimension) is a non-specific factor that relates to both depression and anxiety, and is 
seen as a measure of severity of psychopathology.  
Phenotypic dimensional and categorical approaches can be externally validated by 
using indices of HPA axis function. Sequential assessment of saliva cortisol is 
frequently used to assess the diurnal cortisol which represents the activity of the HPA 
axis under basal conditions. Previous studies indicate that the CAR is under a distinct 
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regulatory influence apart from the decline of cortisol over the day, and, therefore, 
should be assessed and analyzed separately.22-24 
We hypothesize that phenotypic tripartite dimensions may reveal underlying 
associations with salivary cortisol in addition to phenotypic DSM-IV categories, 
because the continuum of dimensional scores includes an indication of severity. 
Moreover, comorbidity is no longer an issue when using a dimensional approach. In 
the present study, we compared the categorical DSM-IV diagnoses with the 
dimensional tripartite model of anxiety and depression as correlates of measures of 
HPA axis function under basal conditions. We used sequential assessments of salivary 
cortisol over the day, to derive HPA axis measures of the CAR and the diurnal 
decline.  
 
Methods 
 
Subjects 
Thirty-six patients suffering from depressive disorders without comorbidity, 18 
patients with anxiety disorders without comorbidity, and 19 patients with comorbid 
depressive and anxiety disorders were recruited from the outpatient department of the 
Rivierduinen mental health center in Leiden, the Netherlands. Patients had to meet 
the criteria of a major depressive disorder and/or an anxiety disorder (i.e., panic 
disorder, social anxiety disorder, obsessive compulsive disorder, generalized anxiety 
disorder or post-traumatic stress disorder) according to the DSM-IV criteria 
confirmed by the Dutch version of the Mini International Neuropsychiatric Interview 
Plus 5.0.0-R (MINI-Plus).25;26 Patients with any other axis I disorders were excluded. 
Forty-three healthy controls were recruited by advertisement. The MINI-Plus was also 
used in healthy controls to rule out current axis I psychopathology. The MINI-Plus 
was administered by trained interviewers. Exclusion criteria were a history of 
neurological or endocrine diseases or other serious unstable medical conditions. 
Furthermore, pregnant or breast feeding women and premenopausal women with 
ovarectomy, and subjects using psychotropic medication with exception of a low dose 
of a benzodiazepine (equivalent to 30 mg oxazepam daily) were excluded. All subjects 
had to be free of psychotropic medication for at least 2 weeks (fluoxetine for six 
weeks), except for a low dose of benzodiazepine,. Additionally, subjects using 
corticosteroids, antidiabetics, estrogens, thyroid hormone, or herbal medication (e.g., 
Valerian, St. Johns Wort) were excluded. All subjects had a routine physical 
examination and laboratory blood tests in order to detect and exclude subjects with 
severe physical comorbidity. Prior to participation, written informed consent was 
obtained from all subjects. The study was approved by the ethics committee of the 
Leiden University Medical Center. 
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Psychological assessments 
The Dutch version of the Mini International Neuropsychiatric Interview Plus 5.0.0-R 
(MINI-Plus)25;26 was used for psychiatric diagnosing according to DSM-IV criteria.  
Subjects completed the Depressive and Anxiety Symptoms Questionnaire 
(MASQ).27;28 The MASQ, based on the tripartite model of anxiety and depression, was 
developed to assess symptoms of depression and anxiety over the previous week. The 
MASQ consists of 90 items, divided into 5 dimensions: 1) anhedonic depression; 2) 
anxious arousal; 3) general distress depression; 4) general distress anxiety, and 5) 
general distress mixed. All items are presented with a 5-point rating scale ranging from 
'not at all' (1) to 'very much' (5). Total scores were calculated by summing all items of 
a particular dimension. The last three dimensions were clustered into one non-specific 
‘general distress’ dimension. In this study the Dutch validated version of the MASQ 
was used.29 The internal consistency of the three MASQ dimensions is excellent (all 
Cronbach’s α≥.88).29  
 
Saliva cortisol sampling 
Face-to-face as well as written instructions concerning saliva sampling prohibited 
eating, smoking, drinking tea or coffee or brushing teeth within 15 minutes before 
sampling. Furthermore, no dental work 24 hours prior to sampling was allowed. Saliva 
samples were obtained at home using salivettes (Sarstedt, Germany) at eight time-
points covering the cortisol awakening response (CAR) and the diurnal decline in 
cortisol. The CAR includes four sampling points; at awakening (T1) and 30 (T2), 45 
(T3) and 60 (T4) minutes after awakening. Four additional samples were taken to 
assess the diurnal decline in cortisol at 11:00h (T5), 15:00h (T6), 19:00h (T7), and 
23:00h (T8). Subjects were asked to register the times they actually sampled in order to 
be able to do a limited check whether participants sampled at the required times. The 
cortisol curve of a single day is determined by situational factors and, to a smaller 
extent, by trait factors.30 Therefore, to reduce measurement error and the effects of 
day-to-day variation, subjects were asked to provide saliva samples on two consecutive 
non-working days. Non-working days were chosen for both patients and controls, 
because hardly any patient was working due to his or her illness. Samples were stored 
at 4 ˚C until bringing them to the clinic, within one week after collection. After 
receipt, salivettes were centrifuged at 2000g for ten minutes, aliquoted and stored at -
20 ˚C. Cortisol analysis was performed by competitive electrochemiluminescence 
immunoassay (Roche, Switzerland), as described in Van Aken et al. 31. The lower 
detection limit was <0.5 nmol/l. The intra-assay coefficients of variance were lower 
than 7%, the inter-assay coefficients of variance were lower than 8%, except for the 
very low range. Per sampling point, physiologically unlikely high values were excluded 
from further analyses (1.3% of the data). We choose a cut-off score of about two 
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standard deviations above the mean, which equals 50 nmol/l. The rationale for 
assuming physiologically unlikely high values is that little wounds in the oral cavity 
might lead to contamination of saliva with blood, resulting in the faulty high cortisol 
levels in saliva. Saliva cortisol levels are reported as nmol/l and showed a normal 
distribution. The two cortisol values obtained at the time points on the 2 days were 
significantly correlated indicating moderate to good intra-individual stability over time 
(r between 0.43 and 0.58, all P≤0.01). Therefore, mean cortisol values for each time 
point were computed for each subject and used in the analyses. If a sample was 
missing, then the value of the other day was used (4.6% of the data points). 
Subjects were asked to report on the following potential confounding factors: 
cigarette smoking, alcohol and coffee consumption, medication and illicit drug use, 
vigorous exercise, time of awakening, time of falling asleep the night before, 
estimation of hours of sleep during the night, the most stressful event of the day, and 
typicality of the day. Body weight and height were measured to calculate the BMI 
(kg/m2).   
 
Statistical analyses 
Group differences for clinical characteristics were assessed by independent t-tests and 
one-way ANOVAs for continuous variables and 2-tests for categorical variables. 
Separate analyses were done for the CAR and diurnal cortisol decline. As markers of 
overall cortisol concentrations, the total area under the curve of the CAR (AUCCAR) 
and diurnal decline (AUCdiurnal) were calculated using the trapezoid formula.32 In 
addition, measures of dynamic change were calculated: the awakening rise (max value 
of T2/T3 minus T1), and the slope of the diurnal decline by estimating a simple linear 
regression model for each subject by regressing the cortisol values at time of collection 
from T5 to T8.  
In addition to the DSM-IV classification, the same group of patients was also 
categorized in tertiles for each MASQ dimension (i.e., upper, middle, lower). One-way 
ANOVA was used for the analysis of group differences in the measures of the CAR 
and diurnal decline. DSM-IV categories and tertiles of the MASQ dimensions were 
entered in subsequent analyses as grouping factor. Trend analyses with polynomial 
contrasts were used when the overall group effect for the phenotypic MASQ 
dimensions was significant, to examine whether this effect could be explained by 
either a linear or non-linear (quadratic) effect.   
All analyses were adjusted for age, gender, body-mass-index (BMI), the use of oral 
contraceptives, and awakening time (only for AUCCAR). Smoking was not included as 
covariate, because there were only 4 smokers in the control group (i.e., 9.3%). In 
addition, analyses were repeated after excluding subjects with post-traumatic stress 
disorder (PTSD), because of contradictory findings found in previous studies.33 
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Analyses were performed using Statistical Package or the Social Science version 16.0 
(SPSS 16.0). P-value < 0.05 was considered statically significant. 
 
Table 1. Clinical characteristics according to DSM-IV patient groups and controls 
 Depressive 
disorder  
(n = 36) 
Anxiety 
disorder 
(n = 18) 
Comorbid 
disorder 
(n=19) 
Controls  
 
(n = 43) 
Age 35.7  12.9 30.3  8.4 28.8  8.7 33.2  12.4 
Gender  
(% women) 
25  
(69.4%)  
14  
(77.8%) 
9  
(47.4%) 
29  
(67.4%) 
Smoking  
(% smokers)a 
21  
(58.3%) 
8 
(50.0%) 
10  
(52.6%) 
4  
(9.3%) 
Contraceptives  
(% female users)a  
13/25  
(52.0%)  
12/14  
(85.7%) 
5/9  
(55.6%) 
10/29  
(34.5%) 
Body-mass-index 
(kg/m2) 
24.4  4.3 22.8  3.5 26.0  8.7 24.4  3.8 
Awakening time  
day 1 (h:mm) 
7:12  0:54 7:41  1:09 7:39  1:11 7:27  0:43 
Awakening time  
day 2 (h:mm) 
7:44  1:10 8:08  1:11 8:07  1:26 7:30  0:57 
Panic  
disorder 
- 6 4 - 
Sociale anxiety  
disorder 
- 9 9 - 
Obsessive compulsive 
disorder 
- 1 1 - 
Generalized anxiety 
disorder 
- 1 0 - 
Post-traumatic stress 
disorder 
- 5 5 - 
MASQ anhedonic 
depressiona,b 
87.8  11.0 69.2  12.1 81.1  12.7 44.0  12.4 
MASQ anxious  
arousala,c  
33.5  13.0 30.0  14.3 30.0  10.0 18.6  1.9 
MASQ general  
distressa,b  
37.8  9.2 30.6  9.7 34.1  8.1 16.8  3.3 
Data are presented as means and standard deviation (SD) or percentage within subgroups. Some patients with 
pure anxiety disorders had more than one anxiety disorder, so the sum does not add up to the total. 
a significant difference between DSM-IV groups compared with controls; b significant difference between DSM-
IV groups mutually; c log-transformed values were used in statistical analyses because of positively skewed 
distributions. 
Cortisol, dimensions and DSM-IV categories 
 60 
Results 
 
Clinical data 
Clinical characteristics are presented in table 1. Patient groups and controls did not 
differ statistically significantly for gender (2=4.30, P=0.23), age (F(3,112)=1.80, 
P=0.15), BMI (F(3,112)=1.21, P=0.31) and time of awakening (day1: F(3,112)=1.47, 
P=0.23; dag2: F(3,112)=2.02, P=0.12) and the awakening times were significantly 
intercorrelated (r=.67, P<0.001).  However, patients were more likely to smoke 
(2=24.52, P<0.001) and, for the female subjects, did more often use oral 
contraceptives (2=9.40, P=0.03) as compared to controls.  
As expected, patient groups scored significantly higher on all MASQ dimensions 
compared to controls (all P<0.01). Significant differences between patient groups 
were found in scores for anhedonic depression (F(2,70)=15.13, P<0.001) and for 
general distress (F(2,70)=4.04, P=0.02), but not for anxious arousal (F(2,70)=0.91, 
P=0.41). Patients with a depressive or comorbid disorder scored higher on anhedonic 
depression and general distress compared to patients with an anxiety disorder.  
When divided in tertiles per MASQ dimension, the three patient groups did not 
differ significantly in age, BMI, smoking and the use of oral contraceptives (data not 
shown). A significant difference was found for gender between the tertiles of anxious 
arousal: females were equally distributed across the tertiles, but males were 
predominantly found in the lower tertile (2=7.89, P=0.02). 
 
Salivary cortisol in the CAR 
Figure 1 shows the CAR for the different approaches to phenotyping. One-way 
ANOVA using the DSM-IV categories as a group factor, revealed neither significant 
differences in AUCCAR nor in awakening rise (Table 2).  
Next, we explored whether MASQ dimensions were associated with the CAR. 
Controls were included in the analyses as a separate group. Significant group 
differences in AUCCAR were found for anhedonic depression and general distress 
(trend), but not for anxious arousal (Table 2). Trend analyses with polynomial 
contrasts were performed to explore whether this group effect could be explained 
either by a linear or a non-linear association between groups and cortisol measures. 
For anhedonic depression and general distress, non-linear associations with the 
AUCCAR were found. Higher cortisol concentrations were found in patients of the 
middle tertile as compared to the lower and upper tertiles, as well as to controls, 
indicating an inverted U-shape (Figure 3). Trend analyses were repeated while 
adjusting for the presence of a depressive and/or anxiety disorder to exclude the 
possibility for non-linear associations to be ascribed to a disproportional distribution 
of the DSM-IV categories across the tertiles. However, non-linear associations 
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remained significant after multivariable adjustment. With regard to the awakening rise, 
only a trend toward significance was found for all three dimensions, i.e., anhedonic 
depression, anxious arousal, and general distress (Table 2). In addition, analyses were 
repeated after excluding subjects with post-traumatic stress disorder (PTSD), because 
of contradictory findings found in previous studies 33. Again, our main findings did 
not change (data not shown).  
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Figure 1. Cortisol awakening response 
Graphical representation of means with bars representing the standard error (SE); patients are subdivided into 
DSM-IV categories (A), and for each MASQ dimension into tertiles (upper, middle, lower) for anhedonic 
depression (B), anxious arousal (C), and general distress (D). 
 
Diurnal decline in salivary cortisol 
Figure 2 shows the diurnal decline for the different approaches to phenotyping. One-
way ANOVA using the DSM-IV categories as group factor revealed significant 
differences in AUCdiurnal and the slope of the diurnal decline (Table 2). Simple contrast 
tests, comparing each DSM-IV category with controls, showed significantly higher 
AUCdiurnal levels and a steeper slope in depressive patients compared to controls 
(t=1.9, P=<0.001; t=-0.74, P=0.01, respectively). 
Next, we explored whether MASQ dimensions were associated with the CAR. 
Controls were included in the analyses as a separate group. Significant group 
differences in the AUCdiurnal were found for anhedonic depression, anxious arousal 
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(trend), and general distress (Table 2). Trend analyses with polynomial contrasts were 
performed to explore whether this group effect could be explained either by a linear 
or a non-linear association between groups and cortisol measures. A linear trend was 
found for anhedonic depression and general distress. Higher dimensional scores were 
related to higher cortisol concentrations during the diurnal cortisol decline. No clear 
linear or non-linear trend could be detected for anxious arousal (Figure 3). With 
regard to the slope of the diurnal decline, no significant group differences were found 
for all dimensions, i.e., anhedonic depression, anxious arousal, and general distress 
(Table 2). Analyses were repeated after excluding subjects with post-traumatic stress 
disorder (PTSD). Our main findings did not change (data not shown).  
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Figure 2. Diurnal decline in salivary cortisol  
Graphical representation of means with bars representing the standard error (SE); patients are subdivided into 
DSM-IV categories (A), and for each MASQ dimension into tertiles (upper, middle, lower) of anhedonic 
depression (B), anxious arousal (C), and general distress (D). 
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Table 2. Cortisol measures accordingly to DSM-IV categories and MASQ tertiles in controls 
and patients with anxiety and/or depressive disorders 
 n AUCCARa Risea AUCdiurnalb Slopeb 
Controls 45 14.6  3.2 2.5  4.4 68.4  21.4 -1.2  1.2 
 
DSM-IV diagnoses: 
     
 Depressive 
disorder 
36 15.3  4.5 5.0  4.3 91.0  33.4 -1.9  1.3 
 Anxiety 
disorder 
18 14.8  4.3 3.1  5.8 69.0  19.3 -1.6  0.6 
 Comorbid 
disorder 
19 15.4  4.8 2.9  4.7 75.7  27.8 -1.3  0.9 
Group effect  
 
 F(3,112)=0.61 P=0.61 
F(3,112)=2.3 
P=0.09 
F(3,112)=5.4 
P=0.002 
F(3,112)=2.7 
P=0.045 
Anhedonic 
depression: 
     
 Lower tertile 23 14.6  4.1 2.6  5.6 73.0  23.1 -1.5  0.6 
 Middle tertile 25 17.4  4.8 5.3  5.3 86.2  27.0 -1.7  1.2 
 Upper tertile 25 13.5  3.9 4.0  3.5 84.6  38.1 -1.8  1.3 
Group effect 
 
 F(3,112)=4.2 P=0.01 
F(3,112)=2.6 
P=0.06 
F(3,112)=2.9 
P=0.04 
F(3,112)=1.9 
P=0.13 
Anxious arousal:      
 Lower tertile 23 15.8  4.6 3.7  5.4 85.2  30.5 -1.8  1.0 
 Middle tertile 25 15.2  4.4 3.5  5.0 74.4  26.3 -1.6  1.1 
 Upper tertile 25 14.5  4.7 4.7  4.3 83.8  33.7 -1.6  1.1 
Group effect 
 
 F(3,112)=1.6 P=0.20 
F(3,112)=2.2 
P=0.09 
F(3,112)=2.2 
P=0.09 
F(3,112)=1.6 
P=0.18 
General distress:      
 Lower tertile 23 15.6  4.9 3.2  5.4 74.1  23.1 -1.7  0.9 
 Middle tertile 25 16.7  4.1 4.6  5.6 86.6  30.4 -1.5  0.9 
 Upper tertile 25 13.4  4.1 4.1  3.5 83.5  36.1 -1.9  1.4 
Group effect 
 
 F(3,112)=2.5 P=0.07 
F(3,112)=2.4 
P=0.08 
F(3,112)=3.4 
P=0.02 
F(3,112)=1.9 
P=0.14 
Data are presented as means and standard deviation (SD) within subgroups; patients are subdivided into 
DSM-IV categories, and for each MASQ dimension into tertiles (lower, middle, upper). Test results of one-
way ANOVAs are presented. 
a Adjusted for age, gender, BMI, use of oral contraceptive, and awakening time. 
b Adjusted for age, gender, BMI, and use of oral contraceptive. 
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Figure 3. AUCCAR and AUCdiurnal of patients with depression and anxiety and controls
Graphical representation of means with bars representing the standard error (SE); patients are subdivided 
in DSM-IV categories (depressive, anxiety, comorbid disorder) and for each MASQ dimension into tertiles 
(lower, middle, upper). P-values of one-way ANOVAs and post hoc trend analyses are presented, adjusted 
for age, gender, BMI, use of oral contraceptive, and awakening time (only for AUCCAR). 
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Discussion 
 
In the present study, we showed that MASQ dimensions are related to the CAR in a 
non-linear pattern, and to the diurnal cortisol decline in a linear pattern. All patients 
with depressive and/or anxiety disorders were free of psychotropic medication.
 Regarding the CAR, cortisol concentrations showed a nonlinear relationship with 
the anhedonic depression and general distress dimension of the MASQ, indicating an 
inverted U-shaped association. This finding would be missed when investigating only 
phenotypic DSM-IV categories. In contrast, the phenotypic DSM-IV categories of 
depressive and anxiety disorders did not show measurable differences in cortisol 
concentrations during the CAR. Our finding of non-linear associations between 
phenotypic dimensions and cortisol concentrations after awakening is in line with 
previous studies in which depressive symptoms were associated with both 
hyperactivity and hypoactivity of the HPA axis.11;12;34 However, these previous studies 
were performed in elderly subjects and did not specifically focus on the CAR. In a 
recent study, a U-shaped association between a dimensional phenotypical approach 
and basal cortisol levels was found. Similar to our findings, cortisol profiles in seniors 
showed that in the extreme ‘highest’ and ‘lowest’ well-being groups, lower cortisol 
levels were found during the first hour after awakening 35. Although the present cross-
sectional study design precludes statements on causation, our finding of an inverted 
U-shaped association between cortisol concentrations in the first hour after awakening 
and MASQ dimensions might suggest that depression and anxiety initially may lead to 
enhanced HPA axis activity, resulting in higher morning cortisol levels. Disease 
progression and increasing severity may eventually lead to a down-regulation of the 
HPA axis, resulting in lower morning cortisol levels.36;37 Previous studies provided 
evidence that an enhanced HPA axis function adapts to chronic and/or severe stress 
by subsequent down-regulation, resulting in a blunted CAR.34;38 Also in a recent meta-
analysis it was shown that timing of the stressor is a critical element in explaining the 
variability in HPA axis function. Hormonal activity is elevated, resulting in elevated 
cortisol output at the stressor onset, but as time passes, this activity diminishes, and 
cortisol secretion rebounds to below normal.39  
Regarding the diurnal cortisol decline, cortisol showed a linear relationship with 
the anhedonic depression and general distress dimensions of the MASQ, indicating 
that increasing dimensional scores were associated with higher cortisol concentrations. 
When using a phenotypic categorical approach, higher cortisol concentrations and a 
steeper slope were found in patients with a DSM-IV depressive disorder compared to 
controls. The linear association between two MASQ dimensions and cortisol 
concentrations during the diurnal decline confirms previous findings in which severity 
of symptoms was related to higher cortisol concentrations.40 The finding of higher 
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cortisol concentrations in depressive patients is also in line with previous studies that 
showed elevated basal cortisol levels in depressive patients during the day. A 
diminished negative feedback or a higher hypothalamic drive might be responsible for 
these higher levels.41-43 With regard to the slope, previous studies found flattened 
circadian slopes (e.g., smaller slopes) in depressive patients, which seems to contrast 
with our finding of steeper slopes.42 This might be due to differences in calculation of 
the slope. Most studies used the time span between awakening and the evening and 
excluded the awakening response. We approached the CAR and diurnal decline as 
separate entities of the cortisol day curve, based on the support of distinct regulatory 
influences to be involved, and calculated the slope of the diurnal decline from 11:00h 
to 23:00h.23 
The non-linear associations during CAR versus the linear associations during the 
diurnal decline support the idea that the cortisol release during the CAR and during 
the diurnal decline are under distinct regulatory influences resulting in different kinds 
of associations (i.e., linear and non-linear) between MASQ dimensions and cortisol 
concentrations.22-24 On the other hand, our study may have been underpowered to 
detect non-linear associations during the diurnal cortisol decline. 
In our study, no cortisol measure was able to discriminate between categories of 
the anxious arousal dimension. This might indicate that the other dimensions, e.g., 
anhedonic depression and general distress, are more closely related to HPA axis 
dysfunction than arousal dimensions. This is in line with previous studies on anxiety 
disorders are characterized by arousal symptoms showing that basal cortisol was 
unaltered as compared to controls.4;6;7;13-17 Otherwise, arousal measures, compared to 
affective measures, might be more subject to temporary fluctuations depending on 
momentary stressors. Therefore trait arousal may be difficult to assess through a 
questionnaire. 
Some methodological limitations of this study should be mentioned. Firstly, 
sample sizes were modest, especially of the pure anxiety group and comorbid group. 
This might have limited the power to detect potential group differences and other 
associations. Secondly, the pure anxiety group and comorbid group were 
heterogeneous, because patients with different anxiety disorders were included. 
However, due to the small number of subjects per anxiety disorder, allocation 
according to diagnosis was not possible. This heterogeneity might also have limited 
the power to detect potential group differences. Thirdly, around 37% of the control 
group and 33% in the patient group showed no rise in cortisol after awakening. At 
least for healthy controls, this percentage is somewhat higher than previous reported 
percentages of 25%, which implies the possibility of non-adherence to the study 
protocol.44;45 Fourthly, previous studies indicate that in psychiatric in-patients with 
more severe forms of psychopathology stronger differences in HPA axis measures 
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were found compared to controls.46-49 We included outpatients and this may have 
reduced the sensitivity to detect DSM-IV group differences in HPA axis function. 
Fifthly, the use of benzodiazepines could have influenced our outcome. However, 
only 4 patients used a low dose of benzodiazepines (maximum of an equivalent to 30 
mg oxazepam daily). Sixthly, we did not collect clinical data on the duration of the 
current episode, age of onset, number of episodes, and presence of psychotic features 
of the depressive and/or anxiety disorder. The hypothesis that an enhanced HPA axis 
reactivity in the short term is followed by down-regulation of the HPA axis in the long 
term should be explored further in longitudinal studies. Lastly, we did not consider 
effects of genotype, personality traits, menstrual cycle, sleep-wake rhythm, and early 
life trauma, all of which might impact HPA axis function.50 
We conclude, firstly, that anhedonic depression and general distress showed non-
linear associations with cortisol concentrations during the CAR in patients with 
depressive and anxiety disorders who were free of psychotropic medication. Secondly, 
linear associations were found between these same MASQ dimensions and cortisol 
concentrations during the diurnal decline. Thirdly, higher cortisol concentrations and a 
steeper slope were found in patients with a DSM-IV depressive disorder compared to 
controls. Although, replication of this study is needed, the present study shows that 
linear and non-linear associations with salivary cortisol are detected when using 
phenotypic dimensions and may be complementary to phenotypic DSM-IV categories 
when doing neuroendocrine research.  
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Abstract  
 
Objective: Depressive and anxiety disorders are associated with an increased risk of 
cardiovascular disease (CVD). Chronic stress induces hypothalamus-pituitary-adrenal 
(HPA)-axis perturbations, which might subsequently induce atherogenic lipoprotein 
profiles and adiposity. The aim of the present study was to investigate the relationship 
between basal saliva cortisol levels and serum lipids and adiposity in psychiatric 
patients. 
 
Methods: Eight salivary cortisol samples (awakening, 30, 45, and 60 min after 
awakening, 11:00h, 15:00h, 19:00h, and 23:00h) on two consecutive days in 
medication-free outpatients with depressive and/or anxiety disorders (n=72) and of 
healthy controls (n=42) were used to derive two measures of HPA-axis function: basal 
cortisol concentrations (i.e., area-under-the-curve (AUCcortisol)) and circadian cortisol 
variability (variabilitycortisol). Index z-scores were calculated for dyslipidaemia (from 
serum triglycerides, inverse high-density lipoprotein cholesterol, and low-density 
lipoprotein cholesterol) and adiposity (from body-mass index and waist-to-hip ratio).  
 
Results: Regression analyses were conducted to determine the contribution of 
AUCcortisol and variabilitycortisol in explaining the variance of respectively the lipid- and 
adiposity-index. Patients showed a higher mean AUCcortisol compared to healthy 
controls (t=2.7; p=.01). Both cortisol parameters were independently associated with 
dyslipidaemia in patients after adjustment for age, alcohol use, and smoking habits 
(=.31, p=.02; and =-.29, p=.02, respectively), but not in controls. Cortisol measures 
were not associated with adiposity in either group.  
 
Conclusions: We conclude that elevated basal cortisol concentrations and lower 
circadian cortisol variability were independently associated with a less favourable 
lipoprotein profile in patients with depressive and/or anxiety disorders. These data 
lend support to the hypothesis that the relationship between affective disorders and 
CVD is partly mediated by HPA-axis perturbations. 
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Introduction 
 
Several studies have shown that depression is associated with an increased morbidity 
and mortality from cardiovascular disease (CVD).1-3 There is growing evidence that 
the same holds for anxiety disorders.4-6 In a part of the patients with depressive and 
anxiety disorders, dysfunctions of the hypothalamic-pituitary-adrenal (HPA) axis are 
observed. The most frequently reported finding is hypercortisolemia under basal 
conditions7;8 Another dysfunction that has been found repeatedly is a lower circadian 
cortisol variability compared to healthy controls.9;10 As cortisol influences many 
metabolic processes, these HPA-axis dysfunctions are plausible mediators of the 
association between depressive and anxiety disorders on the one side and CVD on the 
other.11 
Cortisol is a stress hormone that has effects not only on blood pressure, glucose 
metabolism, and the immune system, but also on lipoprotein metabolism and body 
composition. It stimulates lipolysis and decreases the activity of lipoprotein lipase, 
partly through its effects on insulin sensitivity. As a consequence of hypercortisolism, 
serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol and 
triglycerides increase, and serum levels of high-density lipoprotein (HDL) cholesterol 
decrease. In the long term, this dyslipidaemia due to a cortisol excess leads to an 
increase in central adiposity,12-14 an elevated body-mass index (BMI) and a higher 
waist-to-hip ratio (WHR).15;16;17;18 These metabolic effects of cortisol are clearly shown 
in studies on the effects of synthetic glucocorticoids during anti-inflammatory and 
immunosuppressive therapy19 and on Cushing’s disease.17;18 In addition, in healthy 
participants a lower circadian cortisol variability was associated with detrimental 
metabolic effects, i.e., high triglycerides, high LDL cholesterol, low HDL cholesterol, 
high BMI, and high WHR.20-23  
Studies on HPA-axis dysfunctions in patients with depressive disorders are scarce 
and show contradictory results. In a large cross-sectional survey of elderly depressed 
patients, high 24h urinary cortisol levels were associated with the metabolic syndrome, 
including high triglycerides and low HDL cholesterol.11 However, in another study 
higher salivary cortisol levels (measured at three time points during the day) were 
associated with lower LDL cholesterol levels in 41 overweight depressed patients 
(BMI > 25 kg/m2), but not in 37 patients of normal weight.24 Anxiety disorders were 
associated with dyslipidaemia,25;26 but to the best of our knowledge, no studies were 
done on the associations between lipids and cortisol levels in anxiety disorders.  
We studied two aspects of the HPA-axis function (i.e., basal cortisol release over 
the day, and circadian cortisol variability as an indicator of the responsivity of the 
stress system). Both HPA-axis functions are known to be disturbed in patients with 
depressive and/or anxiety disorders and are hypothesized to be related to a 
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detrimental lipid metabolism and adiposity. As far as we know, no previous study 
focused on both aspects of HPA-axis function and their relationship with parameters 
of dyslipidaemia and adiposity in patients with depressive and anxiety disorders. As 
psychotropic medication is a potential confounder that may affect body weight, serum 
lipids and lipoproteins levels27;28 as well as cortisol levels, we included only patients 
free of such medication. 
 
Methods 
 
Participants 
Seventy two patients suffering from a depressive and/or anxiety disorder were 
recruited from the outpatient department of the mental health center Rivierduinen in 
Leiden, the Netherlands. The Diagnostic and Statistical Manual of Mental Disorders 
(DSM)-IV diagnoses were confirmed by trained interviewers using the Dutch version 
of the Mini International Neuropsychiatric Interview Plus 5.0.0-R (MINI-Plus).29;30 
Patients with any other axis I disorder were excluded. Axis I psychopathology was also 
ruled out by the MINI-plus in 42 healthy controls recruited by advertisement. 
Exclusion criteria were a history of neurological or endocrine diseases or other serious 
medical conditions. Furthermore, participants with substance or alcohol abuse, as well 
as pregnant or breast feeding women and premenopausal women with ovarectomy 
were excluded.  Participants using psychotropic medication with exception of a low 
dose of a benzodiazepine (equivalent to 30 mg oxazepam daily) were also excluded. If 
psychotropic medication was used within the last 14 days (for fluoxetine six weeks) 
participants were excluded. Additionally, participants using corticosteroids, 
antidiabetics, estrogens, thyroid hormone, or herbal medication (e.g., Valerian, St. 
Johns Wort) were excluded. All participants had a routine physical examination and 
laboratory blood tests. Prior to participation, written informed consent was obtained 
from all participants. The study was approved by the ethics committee of the Leiden 
University Medical Center. 
 
Saliva cortisol measures 
Instructions concerning saliva sampling prohibited eating, smoking, drinking tea or 
coffee or brushing teeth within 15 minutes before sampling. Furthermore, no dental 
work 24 hours prior to sampling was allowed. Saliva samples were obtained using 
Salivettes (Sarstedt, Germany) at eight time-points covering the cortisol day curve. 
Four samples were collected at awakening (T1) and 30 (T2), 45 (T3) and 60 (T4) 
minutes after awakening. Four additional samples were taken at 11:00h (T5), 15:00h 
(T6), 19:00h (T7), and 23:00h (T8). The cortisol curve of a single day is determined by 
situational factors and, to a smaller extent, by trait factors. Therefore, to reduce 
Chapter 5 
 
 77 
measurement error and the effects of day-to-day variation,31 participants were asked to 
provide saliva samples on two consecutive non-working days. Non-working days were 
chosen for both patients and controls, because hardly any patients were working due 
to their illness. Samples were stored at 4 ˚C until bringing them to the clinic, within 
one week after collection. After receipt, salivettes were centrifuged at 2000g for 10 
minutes, aliquoted and stored at -20 ˚C. Cortisol analysis was performed by 
competitive electrochemiluminescence immunoassay (Roche, Switserland), as 
described in Van Aken et al..32 The lower detection limit was <0.50 nmol/l. The intra-
assay coefficients of variance were lower than 7%, the inter-assay coefficients of 
variance were lower than 8%, except for the very low range. Per sampling point, 
physiologically unlikely high values (defined as > 50 nmol/l) were excluded from 
further analyses (1.3% of the data). Saliva cortisol levels are reported as nmol/l and 
showed a normal distribution. The two cortisol values obtained at the time points on 
the 2 days were significantly correlated, indicating moderate to good intraindividual 
stability over time (r between .42 and .68, p ≤ .01). Therefore, mean cortisol values for 
each time point were computed for each subject and used in the analyses. If a sample 
was missing, then the value of the other day was used (for 2.9% of the data).  
 
Anthropometric, lipid, and lipoprotein measures 
Body weight and height were measured to calculate the BMI (kg/m2).  The waist 
circumference was measured midway between the lower costal and iliac crest and the 
hip circumference was measured at the level of the great trochanters, to calculate the 
WHR. 
Venous blood was sampled with standard venipuncture techniques. Non-fasting 
triglycerides, total cholesterol and HDL cholesterol (HDL-C plus 3rd generation) were 
measured in serum by automated enzymatic colorimetric methods using a Modular P 
analyzer (Roche, Switzerland). LDL cholesterol was calculated according to the 
Friedewald-formula.33 
 
Statistical analyses 
The area under the cortisol day curve (AUCcortisol) was used as an indicator of the total 
cortisol excretion over the day, calculated using the trapezoid formula 34. The AUC of 
the first four samples at awakening (i.e., T1 to T4) was added to the AUC of the last 
four samples (i.e., T5 tot T8), because the time between the assessment of T4 and T5 
varied depending on the time of awakening. For determination of the circadian 
variability in salivary cortisol (variabilitycortisol), the within-individual variance between 
all cortisol assessments (8 samples x 2 days) was calculated. Variabilitycortisol was log-
transformed, because of its positively skewed distribution. For illustrative purposes, 
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figure 1 represents 2 individual participants with, respectively, a high and low circadian 
cortisol variability. 
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Figure 1. Circadian cortisol variability 
Graphical representation of salivary cortisol values (means from 2 sampling days) of 2 individual participants 
with either a high or low circadian cortisol variability. Figure is included for illustrative purposes to demonstrate 
the concept circadian cortisol variability. 
 
Group differences for clinical characteristics, lipids, lipoproteins, BMI, WHR, and 
cortisol measures (i.e., AUCcortisol and variabilitycortisol) were assessed by independent t-
tests and one-way ANOVAs for continuous variables and 2-tests for categorical 
variables. Next, associations between cortisol measures, lipoprotein profiles, and 
adiposity were examined in patients and controls. Lipid- and adiposity-indices were 
calculated for each subject. For the lipid-index, a mean score of the individual z-scores 
of triglycerides, LDL cholesterol, and inverted HDL cholesterol was calculated, 
corrected for gender and use of oral contraceptives.35 For the adiposity-index, a mean 
score of the individual z-scores of BMI and WHR was calculated, corrected for gender 
and use of oral contraceptives. Univariate and multivariate linear regression analyses 
were conducted to determine the individual and independent contribution of 
AUCcortisol and variabilitycortisol in explaining the variance of respectively the lipid- and 
adiposity-index in the patient group and the control group. All regression analyses 
were adjusted for time of awakening, age, smoking (yes/no), and alcohol consumption 
(daily-weekly/monthly-none). Analyses were performed using Statistical Package for 
the Social Science version 16.0 (SPSS 16.0). P-value < 0.05 was considered statically 
significant. 
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Results 
 
Differences between patients and healthy controls 
Clinical characteristics are presented in table 1. Females showed significant higher 
HDL cholesterol levels (t=3.5, p=.001), and a significant lower WHR (t=-9.0, p<.001) 
than males. Therefore, lipid- and adiposity-indices were adjusted for gender (and oral 
contraceptives) in order to take the effects of confounding into account. Patients and 
controls did not differ statistically significantly for gender, age, BMI, and WHR. 
However, patients were more likely to smoke (2=22.5, p<.001) and, for the female 
participants, did more often use oral contraceptives (2=6.4, p=.01) as compared to 
controls. No statistically significant differences between patients and controls were 
found in serum lipid and lipoprotein levels, but patients showed lower HDL 
cholesterol levels than controls (t=-3.3, p=.001). Patients showed a higher AUCcortisol 
values compared to controls (t=2.7; p=.01), but a comparable variabilitycortisol (t=-.04; 
p=.97).  
 
Table 1. Clinical characteristics, serum lipid and lipoprotein levels, anthropometric measures, 
and cortisol measures in 72 patients with depressive and anxiety disorders and 42 healthy 
controls 
             Patients   Controls  p-   
             (n=72)   (n=42)   value 
Age            32.5  11.3  33.3  12.5 .72  
Gender (% females)        47 (65.3%)  28 (66.7%) .88 
Smoking (% smokers)       39 (54.2%)  4 (9.5%)  < .001 
Alcohol (% consumers)      38 (52.8%)  29 (69.1%) .06 
Oral contraceptives (% users in females) 30/47 (63.8%) 9/28 (32.1%) .01 
BMI (kg/m2)         23.9  4.1   24.3  3.7  .63 
WHR - males         .94  .07   .94  .05  .82 
  - females         .84  .05   .83  .04  .24 
Total cholesterol (mmol/l)     4.80  1.08  4.88  1.11 .73 
Triglycerides (mmol/l)       1.52  .86   1.41  .79  .53 
LDL cholesterol (mmol/l)      3.11  .93   3.08  .99  .87 
HDL cholesterol (mmol/l)     1.56  .40   1.82  .42  .001 
AUCcortisol (nmol/l/h)       96.8  32.0  81.8  23.2 .01 
Variabilitycortisol (nmol2)a      36.9  27.8  33.4  19.7 .97 
Data are presented as means ± standard deviation (SD) or n (percentage within group); 
a log-transformed values used in t-test, because of positively skewed distributions. 
BMI = body-mass index; WHR = waist-to-hip ratio; LDL = low-density lipoprotein; HDL = high-density 
lipoprotein; AUC = area-under-the-curve. To convert values for cholesterol and triglycerides from mmol/l of to 
mg/dl, multiply respectively by 38.7 and 88.8. 
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Associations in the patients 
The lipid- and adiposity-indices were significantly correlated (r=.51, p=<.001). The 
correlation between AUCcortisol and variabilitycortisol showed a low correlation 
coefficient (r=.22, p=.07), indicating them to be relatively independent.  In univariate 
regression analyses, AUCcortisol was a significant predictor of the lipid-index. 
Variabilitycortisol was not significantly associated with the lipid-index (Table 2). In 
multivariate models, however, AUCcortisol and variabilitycortisol were independently 
associated with the lipid-index, after adjustment for age, smoking status, and alcohol 
consumption (Table 2). High AUCcortisol and a low variabilitycortisol were independently 
predictive for a less favourable lipid/lipoprotein profile. Univariate and multivariate 
models showed no significant associations between the two cortisol measures and the 
adiposity-index (Table 2).  
 
Table 2. Univariate and multivariate associations between lipid index, adiposity-index and 
cortisol measures in patients with depressive and anxiety disorders and in healthy controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standardized regression coefficients (β) and p-values are presented;  
a log-transformed values because of positively skewed distribution; 
 b adjusted for age, smoking, and alcohol consumption;  
Lipid-index = mean score of the individual z-scores for triglycerides, LDL cholesterol, and inverse HDL 
cholesterol, adjusted for gender and use of oral contraceptives;  
Adiposity-index = mean score of the individual z-scores for BMI and WHR, adjusted for gender and use of 
oral contraceptives. 
 
 Patients (n=72) 
 Unadjusted 
(univariate) 
Unadjusted 
(multivariate) 
Adjustedb 
(multivariate) 
 β p β p β p 
Lipid-index 
▪ AUCcortisol 
 
.24 
 
.048 
 
.28 
 
.02 
 
.31 
 
.02 
▪ Variabilitya -.10 .42 -.17 .16 -.29 .02 
Adiposity- index 
▪ AUCcortisol 
 
.09 
 
.47 
 
.05 
 
.71 
 
.09 
 
.51 
▪ Variabilitya .20 .10 .19 .13 .08 .54 
 Controls (n=42) 
Lipid-index 
▪ AUCcortisol 
 
.10 
 
.54 
 
.10 
 
.57 
 
.02 
 
.89 
▪ Variabilitya .04 .81 .02 .89 .08 .64 
Adiposity- index 
▪ AUCcortisol 
 
.08 
 
.62 
 
.03 
 
.84 
 
-.01 
 
.97 
▪ Variabilitya .21 .19 .20 .23 .17 .30 
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Next, we explored the associations with individual lipids and lipoproteins. BMI was 
added as predictor to the final model, because of its strong association with lipid and 
lipoprotein levels. In the final model, variabilitycortisol was predictive for triglyceride 
levels and AUCcortisol was predictive for HDL cholesterol. BMI was an independent 
predictor for almost all serum lipids and lipoproteins (Table 3). When analyses were 
repeated while adjusting for the presence of depressive disorder (yes/no) and/or 
anxiety disorder (yes/no), our main findings were not importantly affected (data not 
shown). 
 
Table 3. Associations between serum lipid levels and cortisol measures in 72 patients with depressive and 
anxiety disorders 
          Unadjusted  Adjustedb   Adjustedc   
            p     p     p 
Cholesterol 
AUCcortisol     .12  .34   .11  .39   .08  .53 
Variabilitycortisola   .07  .60   -.17 .17   -.18 .14 
BMI                 .22  .06 
Triglycerides 
AUCcortisol     .24  .06   .18  .19   .12  .33 
Variabilitycortisola   -.17 .18   -.26 .05   -.28 .02 
BMI                 .41  .001 
HDL cholesterol  
AUCcortisol     -.28 .02   -.31 .02   -.26 .03 
Variabilitycortisola   .29  .02   .17  .17   .18  .12 
BMI                 -.32 .01 
LDL cholesterol 
AUCcortisol     .18  .15   .20  .15   .16  .23 
Variabilitycortisola   -.02 .86   -.21 .11   -.22 .09 
BMI                 .25  .048 
Standardized regression coefficients (β) and p-values are presented;  
a logtransformed values because of skewed distribution of data;  
b adjusted for age, gender, use of oral contraceptives, smoking (yes/no) alcohol consumption (daily-
weekly/monthly-none), and presence of depressive (yes/no) and/or anxiety disorders (yes/no);  
c additionally adjusted for BMI. 
 
Associations in healthy controls 
The lipid-index and adiposity-indices were significantly correlated (r=.52, p=.001). 
Again, the correlation between AUCcortisol and variabilitycortisol was not statistically 
significant (r=.22, p=.16). Univariate and multivariate analyses showed no significant 
associations between AUCcortisol and variabilitycortisol and the lipid-index. Furthermore, 
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no significant associations were found between AUCcortisol and variabilitycortisol and the 
adiposity-index (Table 2).   
 
Discussion 
 
In the present study, higher basal cortisol concentrations were found in patients with 
depressive and/or anxiety disorders as compared to controls. In patients elevated 
basal cortisol concentrations and lower circadian cortisol variability were 
independently associated with a less favourable lipoprotein profile (i.e., higher scores 
on the lipid-index). However, no associations were found between cortisol measures 
and indices of adiposity, although the adiposity-index was strongly associated with 
dyslipidaemia.  
The elevated basal cortisol concentrations we found, have been reported 
frequently for these patient groups.7;8 Our findings on the association between 
elevated cortisol levels and dyslipidaemia in our patient group (mean age 32.8  11.7) 
are in line with a study that showed associations between high 24h urinary cortisol 
levels and metabolic syndrome (which includes dyslipidaemia) in elderly depressed 
patients (mean age 74.1 6.6).11 This indicates that the positive association between 
cortisol and dyslipidaemia is not limited to elderly depressed patients. Associations 
were also found  between glucocorticoid administration after organ transplant and 
hyperlipidaemia.15;16;36 Furthermore, it was previously shown in healthy subjects that a 
low circadian cortisol variability, measured in saliva samples, is related to a less 
favourable lipoprotein profile.21-23 Such association was confirmed in our patients, but 
not in controls, maybe because our controls did not show low circadian variability. In 
summary, the present study supports the hypothesis that elevated basal cortisol 
concentrations and lower circadian cortisol variability induce dyslipidaemia in patients 
with depressive and/or anxiety disorders. 
In contrast to some previous studies21;23 we did not find a relationship between 
cortisol and the adiposity-index. Several factors might contribute to this difference. 
Firstly, the mean BMI of our participants was about 3 to 4 points lower than in most 
other studies.21;23 Secondly, other important factors such as lifestyle behaviours might 
contribute more to the development of adiposity in patients with depressive and 
anxiety disorders than HPA-axis perturbations, more specifically changes in dietary 
intake, sleep and less physical activity.37 Thirdly, adiposity might be a long term 
consequence of cortisol excess via dyslipidaemia. Our outpatient group might have 
been less chronically depressed to be able to assess this effect. Fourthly, individual 
differences in depressive symptoms (e.g., high versus low appetite) may make it 
difficult to detect associations between cortisol and indices of adiposity. Fifthly, other 
neuroendocrine pathways might be involved, including the central sympathic nervous 
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system, the gonadal and growth hormone axes, as well as leptin levels.38 Lastly, 
hypercortisolism seems to be involved in central rather than peripheral adiposity,38 
and we did not directly assess the intra-abdominal fat mass.  
Our data support the hypothesis that the higher risk of CVD in patients with 
affective disorders may partly be explained through the direct effects of HPA-axis 
perturbations on lipoprotein metabolism. With respect to HPA-axis dysfunctions, an 
excess of glucocorticoids could contribute to insulin resistance, resulting in increased 
lipolysis through inhibition of lipoprotein lipase. Increased lipolysis results in 
increased serum levels of LDL cholesterol, total cholesterol, and triglycerides and 
decreased serum levels of HDL cholesterol.39 Little is known about the associations 
between low circadian cortisol variability in patients with depressive and anxiety 
disorders and lipid metabolism. It could be hypothesized that a lower cortisol 
variability marks dysfunctions of the HPA-axis and other endocrine axes that 
subsequently affect lipid metabolism.20;21;40 
Some methodological limitations of the present study should be mentioned. 
Firstly, participants were non-fasting prior to blood sampling for logistical reasons, 
while food intake is known to increase triglycerides levels. Furthermore, associations 
between lipid/lipoproteins and cortisol might have been weakened, because blood 
was collected between participants at different time points during the day (mostly at 
9:00h or at 14:00h). Nevertheless, significant associations between the index scores of 
dyslipidaemia and cortisol measures were found. Secondly, no electronic monitoring 
of compliance to the sampling protocol was performed.41;42 Therefore, non-adherence 
could have affected our data. Thirdly, although we adjusted for several potential 
confounders, other confounders might have influenced our outcome, such as the 
duration of the disease, the age of onset, and specific symptoms such as sleep 
disturbances. Fourthly, the sample size was relatively small. Lastly, the lumping of 
patients with depressive and anxiety disorders in a single group might have prevented 
us from finding more clear-cut results. However, in our opinion this is justified 
because of the extensive co-morbidity and indications for shared psychopathological 
processes.43;44 Moreover, we adjusted for the presence of a depressive and/or anxiety 
disorder and this did not change our results.  
We conclude that elevated basal cortisol concentrations and lower circadian 
cortisol variability were independently associated with a less favourable lipoprotein 
profile, but not with indices of adiposity in patients with depressive and/or anxiety 
disorders. These associations were not found in healthy controls. Perturbations of the 
HPA-axis in patients might partly explain the increased risk of CVD through its 
effects on lipoprotein metabolism. Our data need replication to confirm our results. 
Furthermore, prospective studies are needed to determine the impact of chronic 
psychological stress on the HPA-axis and its metabolic consequences.  
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Abstract 
 
Objective: Cortisol effects the acute-phase response, but it is unknown whether C-
reactive protein (CRP), a proinflammatory acute-phase reactant, also affects 
hypothalamus-pituitary-adrenal (HPA) axis activity. In the present study associations 
were explored between CRP haplotypes with plasma CRP levels and basal salivary 
cortisol.  
 
Methods: We included 266 physically healthy Caucasian subjects of whom 94 had a 
psychiatric disorder in a genetic association study. Six tag single nucleotide 
polymorphisms (SNPs) capturing the common genetic variation of the CRP gene were 
genotyped (i.e., rs2808628, rs2808630, rs1205, rs1800947, rs1417938, and rs3091244) 
to yield common CRP haplotypes. Plasma CRP levels, the salivary cortisol awakening 
response (CAR) (0, 30, 45, and 60 min after awakening), and the diurnal cortisol 
decline (11:00h, 15:00h, 19:00h, and 23:00h) were assessed.  
 
Results: Rs2808628, rs1205, rs1417938, and rs3091244 showed expected associations 
with CRP levels and salivary cortisol during the CAR. The 5 most common CRP 
haplotypes were ordered linearly according to wellcharacterized increasing CRP levels. 
There was an inverse linear association between CRP haplotypes and cortisol levels 
during the CAR, but no association with the diurnal cortisol decline.  
 
Conclusion: Genetic variants in the CRP gene are associated not only with higher 
plasma CRP levels but also with lower salivary cortisol levels after awakening, in basal, 
non-inflammatory conditions. 
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Introduction 
 
The immune system and the hypothalamus-pituitary-adrenal (HPA) axis play 
important roles in maintaining homeostasis by generating adaptive responses to 
noxious stressors.1;2 C-reactive protein (CRP), a proinflammatory acute-phase 
reactant, and cortisol, the main stress hormone of the HPA axis, are both involved. 
CRP is predominantly produced in the liver and its release is regulated by an 
inflammatory cascade of reactions, which involve, among others, proinflammatory 
cytokines.3;4 Cortisol acts synergistically with the proinflammatory cytokine 
interleukine (IL)-6 to enhance this effect.5 The main biological function of CRP is its 
ability to recognize pathogens and damaged cells of the host and to mediate their 
elimination by recruiting the complement system, which subsequently activates and 
attracts phagocytic cells4 CRP induces the release of proinflammatory cytokines IL-1, 
IL-6, and TNF-α by these cell.6 On the other hand, cortisol is a potent endogenous 
anti-inflammatory agent with immunosuppressive effects. It has a strong capacity to 
suppress immune cell functions, such as inhibiting the release of proinflammatory 
cytokines. Not much is known yet about the direct pathway from CRP to cortisol 
release. However, the bidirectional relationship between CRP and cortisol is assumed 
to play an important role in maintaining the physiological homeostasis.2  
 Environmental variables and lifestyle behaviours such as dietary intake, smoking, 
acute and chronic infections, gender, lipid levels, obesity, and blood pressure can 
contribute to variations in both CRP levels and cortisol levels.7-9 These variables might 
also influence the potential cross-sectional relationship between CRP and cortisol. 
Mendelian randomization refers to the random assortment of genes from parents to 
offspring that occurs during gamete formation and conception.10;11 It provides a 
method to assess, relatively unconfounded, whether CRP – that has an important 
genetic component of about 35-40%12 – is causally related to salivary cortisol. Several 
well-characterized CRP gene polymorphisms are known to be associated with plasma 
CRP levels, e.g., rs2808628, rs2808630, rs1205, rs1800947, rs1417938, and 
rs3091244.12-15 
In the present study we assessed these CRP polymorphisms in a Mendelian 
randomization design in order to elucidate the relationship between plasma CRP levels 
and basal salivary cortisol levels over the day under non-inflammatory conditions. We 
tested the hypothesis that haplotypes of the CRP gene that affect plasma CRP levels, 
are also associated with basal salivary cortisol levels, especially with cortisol during the 
awakening response, that shows substantial heritability (40-48%).16 As indices of 
activity of the HPA axis, we used sequential assessments of salivary cortisol over the 
day to derive measures of the cortisol awaking response (CAR) and the diurnal 
decline. 
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Methods 
 
Subjects 
We included 266 physically healthy subjects, of whom 94 subjects had a depressive 
and/or anxiety disorder. Data were collected as part of studies on psychiatric and 
neuroendocrine correlates of the HPA axis.17;18 Non-psychiatric subjects were 
recruited by advertisement in local news papers asking for physically and mentally 
healthy persons willing to participate in a study on the biological stress system in 
relation to depression and anxiety. Psychiatric subjects were included from the 
outpatient department of the Rivierduinen mental health center in Leiden, the 
Netherlands. We allocated non-psychiatric and psychiatric subjects to one 
experimental group to increase the sample size and statistical power. Exclusion criteria 
were a history of neurological or endocrine diseases or other serious or unstable 
medical conditions. Furthermore, subjects with substance or alcohol abuse, as well as 
pregnant or breast feeding women and premenopausal women with ovariectomy were 
excluded.  Subjects were excluded when using psychotropic medication within the last 
14 days, also corticosteroids, antidiabetics, estrogens, thyroid hormone, or herbal 
medication (e.g., Valerian, St. Johns Wort) were excluded. All subjects had a routine 
physical examination and laboratory blood tests, excluding a.o. acute infections and 
chronic inflammatory diseases. Prior to participation, written informed consent was 
obtained from all subjects. The study was approved by the ethics committee of the 
Leiden University Medical Center. 
 
Saliva cortisol sampling 
Instructions concerning saliva sampling prohibited eating, smoking, drinking tea or 
coffee or brushing teeth within 15 minutes before sampling. Furthermore, no dental 
work 24 hours prior to sampling was allowed. Saliva samples were obtained using 
Salivettes (Starstedt, Germany) at eight time-points covering the cortisol awakening 
response (CAR) and the diurnal decline in cortisol. The CAR includes four sampling 
points; at awakening (T1) and 30 (T2), 45 (T3) and 60 (T4) minutes after awakening. 
Four additional samples were taken to assess the diurnal decline in cortisol at 11:00h 
(T5), 15:00h (T6), 19:00h (T7), and 23:00h (T8). Subjects registered each time a 
sample was collected in order to be able to do a limited check whether subjects 
sampled at the required times. The cortisol curve of a single day is determined by 
situational factors and, to a smaller extent, by trait factors.19 Therefore, to reduce 
measurement error and the effects of day-to-day variation, subjects were asked to 
provide saliva samples on two consecutive non-working days. Samples were initially 
stored at 4 ˚C for a week at most and delivered by the subject to our clinic. After 
receipt in our clinic, salivettes were centrifuged at 2000g for ten minutes, aliquoted 
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and stored at -20˚C. After receipt, salivettes were centrifuged at 2000g for ten minutes, 
aliquoted and stored at -20˚C. Cortisol analysis was performed by competitive 
electrochemiluminescence immunoassay (Roche, Switserland), as described in Van 
Aken et al. 20. The lower detection limit was 0.50 nmol/l. The intra-assay coefficients 
of variance were lower than 7%, the inter-assay coefficients of variance were lower 
than 8%, except for the very low range. Per sampling point, physiologically unlikely 
high values (i.e., > 50 nmol/l) were excluded from further analyses (1.3% of the data). 
Saliva cortisol levels are reported as nmol/l and showed a normal distribution. The 
two cortisol values obtained at the time points on the 2 days were significantly 
correlated indicating moderate to good intra-individual stability over time (Pearson’s r 
between 0.45 and 0.65, p ≤ 0.001). Therefore, mean cortisol values for each time 
point were computed for each subject and used in the analyses. If a sample was 
missing, then the value of the other day was used (2.9% of the data). 
  
Plasma CRP measurement 
Venous blood was sampled with standard venipuncture techniques. CRP levels were 
measured in plasma by automated enzymatic colorimetric methods using a Modular P 
analyzer (Roche, Switzerland) with a lower limit of detection being 3 mg/l.  
 
Single nucleotide polymorphism genotyping 
Genomic DNA was isolated from the blood samples according to standard 
procedures. Single nucleotide polymorphisms (SNPs) in the CRP gene were 
determined the frequency of six well-characterized CRP polymorphisms that showed 
to be related with plasma CRP levels (Figure 1). I-plex assays were assigned using 
Assay designer software (Sequenom). Genotyping was performed using the MassArray 
platform according to the manufacturer’s protocols (Sequenom, San Diego, CA). 
After PCR on 2.5 ng of DNA, a primer tension reaction was performed to introduce 
mass differences between alleles. After removing salts by adding a resin, 15 nL of the 
product was spotted onto a target chip with 384 patches containing matrix. Mass 
differences were detected using the Brucker Autoflex MALDI-TOF mass 
spectrometer, and genotypes were assigned real-time user Typer 3.1 software 
(Sequenom). As quality control, 10% of samples were genotyped in duplicate, and no 
inconsistencies were observed.  
 
Statistical analyses 
The haplotype frequencies were reconstructed using SNPHAP (Clayton, 2002; version 
1.3; available online at http://www-gene.cimr.cam.ac.uk/clayton/software/) with an 
estimation-maximization algorithm.  Haplotypes were placed in the order that 
previously showed to be associated with increasing plasma CRP levels.15;21 Each of the 
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CRP polymorphisms was assessed to determine if the observed genotype frequencies 
were consistent with the expected Hardy-Weinberg proportions by using the χ2-test. 
The Linkage Disequilibrium (LD) was assessed using Lewontin’s D’ statistics.22 
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Figure 1. Schematic overview of the structure of the C-reactive protein (CRP) gene, consisting of 2 exons 
seperated by a single intron 
The orientation of the gene is marked by arrows, with the gene transcribed from left to right. All single 
nucleotide polymorphisms (SNPs) were in Hardy-Weinberg equilibrium (HWE; all p’s ≥ 0.15). Arrows 
mark the approximate location on chromosome 1 of the 6 tagSNPs that were in close linkage disequilibrium 
(D’ for all SNP pairs ≥0.96, except for 2 pairs with ≥0.90). The 5 most frequent haplotypes are presented, 
that are similar to those found in populations from Northern and Western European ancestry. rs3091244 is a 
tri-allelic SNP located in the promotor region of the CRP gene. 
 
As markers of overall cortisol levels, the total area under the curve of the CAR 
(AUCCAR) and diurnal decline (AUCdiurnal) were calculated using trapezoid formula 23. 
Furthermore, subjects were dichotomized according to the CRP-level (> 3 mg/l = 
high risk and  3 mg/l  = low/average risk). The cut points of low/average risk (< 3.0 
mg/l), and high risk (> 3.0mg/l) correspond to approximate tertiles of high-sensitivity 
(hs)-CRP in the adult population.24 Subjects with > 3.0 mg/l hs-CRP levels are at an 
increased risk for cardiovascular disease (estimated odds ratio 2.0) and depression 
(estimated odds ratio 1.6 in men).24;25  
Binary logistic and linear regression analyses were used to investigate associations 
between polymorphisms and haplotypes with changes in plasma CRP levels and 
salivary cortisol levels. Analyses were adjusted for age, gender, smoking status 
(yes/no), body mass-index (BMI) and group (presence/absence of affective disorder). 
Non-psychiatric and psychiatric subjects were combined because of the relatively low 
number of subjects per group to increase statistical power. Analyses were performed 
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using Statistical Package or the Social Science version 16.0 (SPSS 16.0; SPSS Inc., 
Chicago, IL, USA). P-value < 0.05 was considered statically significant. 
 
Results 
 
Study population 
The mean age of the study population was 40.1  13.1 years. The study population 
consisted of 103 females (38.7%) and 163 males (61.3%) and 38.3% of the subjects 
were smokers. The mean BMI of the study population was 25.3  4.5 kg/m2. The 
genotypes frequencies are listed for each polymorphism in table 1. Rare genotypes 
(<1%) for rs3091244 and rs1800947 were subsequently collapsed. The genotype 
frequencies of all polymorphisms were in Hardy-Weinberg equilibrium (Ps>0.15). All 
single nucleotide polymorphisms (SNPs) were in Hardy-Weinberg equilibrium (HWE; 
all p’s ≥ 0.15). The six polymorphisms were in close linkage disequilibrium (D’ for all 
SNP pairs ≥0.96, except for 2 pairs with ≥0.90). 
 
Associations with individual CRP genotypes (table 1) 
Plasma CRP levels showed the expected differences among subjects with different 
genotypes of rs2808628, rs1205, rs1417938, and rs3091244. Rs1800947 showed a 
trend towards significance (p=0.08), but this trend was lost after adjustment for 
covariates (p=0.15).  
The CRP polymorphisms that were related to differences in plasma CRP levels 
also showed significant differences in cortisol AUCCAR values (i.e., rs1205, rs1417938, 
rs3091244, and a trend for rs2808628). For the CRP polymorphism rs1205, the CC 
genotype was associated with lower cortisol AUCCAR values. For the CRP 
polymorphism rs1417938, the AA genotype was associated with lower cortisol 
AUCCAR values. For the CRP polymorphism rs3091244, the TT/TA/AA genotype 
was associated with lower cortisol AUCCAR values. For the CRP polymorphism 
rs2808628 a trend towards significance was found for the association with lower 
cortisol AUCCAR values. CRP polymorphisms rs1800947 and rs2808630 did not show 
differences in cortisol AUCCAR values between the genotypes. No significant 
associations were found between CRP polymorphisms and cortisol AUCdiurnal values.  
The CRP levels (as a continuous variable) were not significant correlated with  
cortisol AUCCAR values and cortisol AUCdiurnal values (respectively, Spearman’s rho = -
0.06, p =0.38, Spearman’s rho = -0.09, p =0.16. 
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Table 1. Plasma CRP levels, AUCCAR values and AUCdiurnal values according to genotype 
frequencies for CRP polymorphisms in 266 subjects 
SNP genotype n High CRP (%) AUCCAR 
(nmol/l/h) 
AUCdiurnal 
(nmol/l/h) 
Rs2808628 
▪ GG 
▪ GA 
▪ AA 
  Missing values 
P-value for trend 
 
111 
113 
40 
2 
 
34 (30.6%) 
20 (17.7%) 
7 (17.5%) 
 
0.01 
 
15.2 (14.3 – 16.1) 
16.0 (15.0 – 16.9) 
16.9 (15.4 – 18.3) 
 
0.06 
 
6.4 (6.0 – 6.9) 
6.7 (6.2 – 7.2) 
6.6 (5.9 – 7.4) 
 
0.57 
rs2808630 
▪ TT 
▪ TC 
▪ CC  
  Missing values 
P-value for trend 
 
140 
108 
17 
1 
 
31 (22.1%) 
28 (25.9%) 
3 (17.7%) 
 
0.75 
 
15.6 (14.8 – 16.5) 
16.1 (15.2 – 17.0) 
15.3 (12.8 – 17.9) 
 
0.76 
 
6.6 (6.2 – 7.1) 
6.4 (5.9 – 6.9) 
6.9 (5.6 – 8.2) 
 
0.79 
rs1205 
▪ CC 
▪ CT 
▪ TT 
  Missing values 
P-value for trend 
 
110 
115 
41 
0 
 
35 (31.8%) 
21 (18.3%) 
7 (17.0%) 
 
0.01 
 
15.1 (14.1 – 16.0) 
16.1 (15.2 – 17.0) 
16.8 (15.3 – 18.3) 
 
0.03 
 
6.4 (6.0 – 6.9) 
6.6 (6.2 – 7.1) 
6.8 (6.1 – 7.6) 
 
0.37 
rs1800947 
▪ GG 
▪ GC/CC 
  Missing values 
P-value for trend 
 
231 
35 
0 
 
59 (25.5%) 
4 (11.4%) 
 
0.15 
 
15.7 (15.0 – 16.3) 
16.6 (15.0 – 18.2) 
 
0.29 
 
6.5 (6.2 – 6.9) 
6.9 (6.1 - 7.7) 
 
0.42 
rs1417938 
▪ TT 
▪ TA 
▪ AA 
  Missing values 
P-value for trend 
 
135 
108 
21 
2 
 
25 (18.5%) 
31 (28.7%) 
5 (23.8%) 
 
0.04 
 
16.3 (15.4 – 17.1) 
15.5 (14.6 – 16.4) 
14.2 (12.1 – 16.2) 
 
0.04 
 
6.7 (6.2 – 7.1) 
6.6 (6.1 – 7.1) 
5.9 (4.8 – 7.0) 
 
0.30 
rs3091244 
▪ CC 
▪ CT/CA 
▪ TT/TA/AA 
  Missing values 
P-value for trend 
 
107 
97 
33 
29 
 
16 (15.0%) 
31 (32.0%) 
8 (24.2%) 
 
0.02 
 
16.5 (15.5 – 17.4) 
16.0 (15.1 – 17.0) 
14.2 (12.6 – 15.9) 
 
0.04 
 
6.6 (6.1 – 7.1) 
7.0 (6.5 – 7.5) 
5.9 (5.0 – 6.8) 
 
0.57 
Percentages of subjects with plasma CRP levels > 3mg/l are presented. Rs3091244 is a triallelic SNP. 
Geometric estimated means adjusted for age, gender, smoking status (yes/no), BMI, and group 
(presence/absence of affective disorder) with 95% confidence intervals are presented for AUCCAR (nmol/l/h) 
and AUCdiurnal (nmol/l/h). Test values of binary logistic regression analysis (plasma CRP) linear regression 
analyses (cortisol measures) were used to test for linear trend. 
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Associations with CRP haplotypes (table 2) 
Five common haplotypes with  1% frequencies were observed (Figure 1). We 
numbered haplotypes in our data set according to previous published increasing 
plasma CRP levels from haplotype 1 to haplotype 5 15;21 and we confirmed the order 
in our data set. A statistically significant linear trend, but in reverse direction, was also 
found for AUCCAR values from haplotype 1 to haplotype 5. No significant associations 
were found between haplotypes and the cortisol AUCdiurnal values (Table 2, Figure 2).  
The frequency of haplotype 1 to 5 in the psychiatric subjects was, respectively, 
3.2%, 33.9%, 25.3%, 28.0%, 9.7%, and in the non-psychiatric subjects, respectively, 
9.0%, 27.0%, 29.9%, 29.7%, and 6.3%. The frequency of the individual haplotypes did 
not differ significantly between psychiatric and non-psychiatric subjects (linear-by-
linear=1.7, p= 0.33), and the effect of group in binary logistic and linear regression 
analyses with plasma CRP levels and AUCCAR were also not significant (p=0.14 and 
p=0.40, respectively). 
 
Table 2. Associations between CRP haplotypes with plasma CRP levels and salivary cortisol 
measures in 266 subjects 
Haplotype 
 
Genotype 
combination 
n High 
CRP (%) 
AUCCAR 
(nmol/l/h) 
AUCdiurnal  
(nmol/l/h) 
1 ATTCTC 36  
(6.8%) 
4  
(11.4%) 
16.1  
(14.5 – 17.7) 
6.8  
(6.1 – 7.6) 
2 ATTGTC 153 
(28.8%) 
31  
(21.0%) 
16.2  
(15.4 – 17.0) 
6.3  
6.2 – 7.0) 
3 GCCGTC 140  
(26.3%) 
34  
(24.6%) 
15.6  
(14.8 – 16.4) 
6.6  
(6.2 – 7.0) 
4 GTCGAT 151  
(28.4%) 
43 
 (29.1%) 
15.0  
(14.3 – 15.8) 
6.4  
(6.0 – 6.8) 
5 GTCGTA 39  
(7.3%) 
13  
(34.2 %) 
15.0  
(13.5 – 16.5) 
6.6  
(5.9 – 7.4) 
Other 
haplotypes 
 13  
(2.4%) 
   
P-value for 
trend 
  0.004 0.03 0.38 
Five common haplotypes were constructed from rs2808628, rs2808630, rs1205, rs1800947, rs1417938, 
and rs3091244. Percentages of subjects with plasma CRP levels > 3 mg/l are presented. Geometric estimated 
means adjusted for age, gender, smoking status (yes/no), BMI, and group (presence/absence of affective 
disorder) with 95% confidence intervals are presented for AUCCAR (nmol/l/h) and AUCdiurnal (nmol/l/h). 
Test values of binary logistic regression analysis (plasma CRP) and linear regression analyses (cortisol measures) 
were used to test for linear trend. Each subject has two haplotypes; total 532 (i.e. 2 x 266). 
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Figure 2. Crude associations between 5 common CRP haplotypes and plasma CRP levels and salivary 
cortisol levels across the day in 266 subjects 
Percentages of subjects with plasma CRP levels > 3mg/l are presented (A). Cortisol assessments in the first 
hour after awakening (B) and during the diurnal decline (C) are presented.  
 
Discussion 
 
The main finding of the present study is that CRP haplotypes were not only associated 
with differences in plasma CRP levels, but also with differences in salivary cortisol 
levels during the awakening response. More specific, the present data showed that 
variants of the CRP gene which were associated with higher CRP levels under basal, 
non-inflammatory conditions, were also associated with lower cortisol levels after 
awakening. These findings support the hypothesis of a relationship between CRP and 
the CAR. To the best of our knowledge, this was the first study that investigated 
associations between CRP gene polymorphisms and cortisol levels using a Mendelian 
randomization design. 
Our finding of associations between CRP polymorphisms (i.e., rs3091244, 
rs1417938, rs2808628, rs1205) and plasma CRP levels is consistent with previously 
published data.12;15;21 In addition, we showed significant associations between the same 
CRP polymorphisms and cortisol levels during the CAR. However, we found no 
associations between CRP polymorphisms and cortisol release during the diurnal 
decline, suggesting that genetic variation in the CRP gene only affects cortisol levels 
after awakening under basal, non-inflammatory conditions. The effects on the 
awakening response may thus be a manifestation of the multiple effects of the CRP 
gene. This is in accordance with findings of previous studies that evaluated the 
heritability of cortisol levels. In a twin study of 52 monozygotic (MZ) and 52 dizygotic 
(DZ) twin pairs, it was concluded that about 40% to 48% of individual differences in 
cortisol release in the first hour after awakening was attributable to genetic factors, 
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whereas no genetic influence was found for the remaining diurnal decline.16 This 
pattern was replicated in a larger study of 199 MZ and 272 DZ adult twin pairs, in 
which the cortisol levels at awakening and 30 minutes later showed around 30% 
heritability, with no significant effects for values recorded later during the day.26 
Furthermore, we confirmed the clear linear trend in increasing plasma CRP levels 
from haplotype 1 to haplotype 5,15;21 but we also found a linear trend, but in inverse 
direction, between CRP haplotypes and cortisol levels after awakening. The 
relationship between CRP and cortisol levels has scarcely been investigated. One study 
showed that the infusion of CRP increases plasma cortisol levels on the short-term.27 
However, CRP infusion leads to an acute increase of CRP to ‘pathophysiological 
levels’, which might interact differentially with cortisol release as compared to more 
longstanding effects of higher CRP levels, which are captured in a Mendelian 
randomization design. In another study, no significant correlation between CRP levels 
and cortisol over the day was found in healthy subjects in a cross-sectional study.28 
The association between CRP and cortisol was not the main focus of that study and 
adjustment for potential confounders was not applied. In general, stressful and 
proinflammatory conditions, such as acute infections, may increase both CRP and 
cortisol levels, due to activation of the immune system and HPA axis. But, previous 
studies showed that in chronic inflammatory conditions, such as rheumatoid arthritis 
and Sjögren’s syndrome,29-31 cortisol levels were not elevated, despite the presence of 
chronic high circulating inflammatory cytokine and CRP levels. This phenomenon was 
referred to as an ‘inadequate’ low cortisol secretion relative to the chronic 
inflammatory status.29;31 It could be hypothesized that a chronic pro-inflammatory 
state with high CRP levels ultimately results adaptation of the HPA axis, through 
negative feedback mechanisms, leading to lower cortisol levels. As persistent high 
cortisol concentrations would predispose to infections,32 such a cortisol decrease may 
be adaptive. Our findings are consistent with this hypothesis of a negative feedback of 
CRP on the HPA axis. We showed that genetically induced higher CRP levels are 
associated with lower cortisol levels. In other words, CRP effects on cortisol may play 
a role in maintaining the stress homeostasis. However, in contrast with the direct 
effects of CRP polymorphisms on CRP levels, the mechanism of effect on cortisol 
levels likely involves a much more complex network of endogenous interactions that 
include cytokines. 
 Some methodological limitations of the present study should be mentioned. 
Firstly, plasma CRP levels were not analyzed with a high sensitivity assay and the 
lower limit of detection was 3 mg/l. Nevertheless, the sensitivity was sufficient to 
confirm the well-known associations between CRP polymorphisms and CRP levels 
found in previous studies. Secondly, our study may have been underpowered with a 
relatively small sample size. Data were collected as part of studies on psychiatric and 
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neuroendocrine correlates of the HPA axis. To increase the statistical power in our 
analyses, we allocated physically healthy subjects with and without a psychiatric 
disorder to one experimental group. Although psychiatric and non-psychiatric subjects 
did not differ in frequency of individual haplotypes, replication in a larger, more 
uniform and healthy cohort is required. Thirdly, the HPA axis may be involved in the 
pathology of psychiatric disorders, that some of the subjects were suffering from. 
However, post-hoc analyses showed no statistical differences between non-psychiatric 
and psychiatric subjects in cortisol levels neither during the awakening response nor 
for the diurnal decline. Moreover, there was no interaction with psychopathology for 
our main effects. Therefore, the effects of CRP polymorphisms on cortisol levels are 
unlikely due to confounding by psychopathology. Fourthly, although we adjusted for 
several potential confounders, other confounders that are likely to affect CRP and/or 
cortisol levels might have influenced our outcome, such as acute (viral) infections. 
Finally, the design of the study needs to be considered. Our study made use of 
naturally occurring genetic variation resulting from independent gene assortment, also 
referred to as Mendelian randomization, as the basis of our analyses of association. 
Variants of nearby genes in linkage disequilibrium with the CRP polymorphisms may 
also explain our findings. 
We conclude that genetic variants in the CRP gene are associated with differences 
in plasma CRP and salivary cortisol levels after awakening under basal, non-
inflammatory conditions, suggesting that CRP metabolism and cortisol release during 
the awakening response are closely linked.  
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Summary 
 
The objective of this thesis is to extend our knowledge on hypothalamus-pituitary-
adrenal (HPA) axis dysfunction in patients with depression and/or anxiety disorders.  
Nearly all previous studies on this topic start with the psychiatric disorder and study 
its relationship with the HPA axis function in comparison to healthy controls.  These 
studies showed inconsistent associations between depression and/or anxiety disorders 
defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV 
defined and HPA axis dysfunctions. A number of studies show a hyperactive HPA 
axis.1-5 However, a normoactive,2;6;7 and hypoactive6;8;9 HPA axis were also found in 
this patient groups. This lack of consistent findings could be explained, at least in part, 
by the limited specificity of the categorical DSM-IV diagnoses. This may be due to the 
overlap of DSM-IV diagnoses by sharing criteria. Furthermore, the presence of non-
linear associations between cortisol levels and psychopathology might also have 
contributed to these inconsistent findings.10;11 In addition, the HPA axis needs to have 
a far-reaching power over the metabolism of the body, because in times of crisis the 
body should be able to acutely redirect metabolism to enable a fight, flight or freeze 
reaction. Therefore, dysfunctions of the HPA axis have to lead to changes in other 
biological systems. So far as known, not much work is done on this issue. Most 
studies compare psychiatric patients and controls on differences in function of the 
biological system under study, but mutual associations between the HPA axis and 
other biological systems, e.g., the metabolic and immune system, are hardly explored. 
 In this thesis we have tried to avoid the shortcomings of the DSM-IV classification 
system by starting with the HPA axis, as key stress system in stress coping. Cortisol, as 
main end product of the HPA axis in man, exerts diverse effects on a wide variety of 
physiological systems. We used cortisol concentrations, in diurnal curves as well as 
assessed in challenge tests, as core parameters by which we attempted to redefine the 
phenotype of psychopathology. In addition, we studied its relationship with the 
metabolic and immune system in patients suffering from depression and/or anxiety 
disorders. 
In the first empirical study (chapter 3) we investigated the functioning of the HPA 
axis in patients with depression and comorbid anxiety disorders, depression alone and 
in healthy controls by means of the dexamethasone (DEX)/corticotropin-releasing 
hormone (CRH) test. We found an enhanced suppression of cortisol to DEX, with 
consequentially a lower cortisol response to CRH in the patient group with 
comorbidity of depression and anxiety disorders compared to the other two groups. 
We concluded that the degree of HPA axis dysfunctions is influenced by comorbidity. 
As previous studies did not pay attention to comorbidity, the influence of comorbidity 
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on HPA axis dysfunctions may partly explain the inconsistencies in the outcomes of 
previous DEX/CRH studies.  
In chapter 2, we argue that the study of the relationship between psychiatric 
symptomatology and an endophenotype like HPA axis functioning should not only 
take comorbidity into account. As variation in psychiatric symptoms is continuous 
they do not coalesce into fairly well-defined categorical DSM-IV clusters. Continuous 
psychological dimensions selected for their predictiveness with respect to 
endophenotypes, as biological intermediate factors, are proposed to be the best ways 
in reaching an understanding of the causations in mood, anxiety, and somatoform 
disorders.  
In chapter 4, we performed an empirical study on this issue. We investigated 
whether cortisol concentrations correlate with continuous phenotypic dimensions 
based on the tripartite model of Watson and Clark. Using these dimensions we found 
linear as well as non-linear associations with salivary cortisol. These non-linear 
associations remained unobserved when categorical diagnoses were used. This might 
be an additional explanation of the inconsistencies found in previous cortisol studies. 
Therefore, a dimensional approach to phenotyping is a promising new way to study 
the relations between phenotype and endophenotype in psychiatric disorders.  
In chapter 5, the relationship between the HPA axis and lipid metabolism and 
adiposity indices in patients with depression and anxiety disorders was explored. 
These indices are predictive of the risk of cardiovascular disease (CVD). They are also 
components of the metabolic syndrome and are often affected in patients with 
depression and/or anxiety disorders. This study extended previous research by 
providing evidence that two states of dysfunction of the HPA axis, i.e., elevated basal 
cortisol levels and lower circadian cortisol variability, were independently related to 
detrimental lipid metabolism, but not to obesity, in patients with depression and/or 
anxiety disorders. We propose that the HPA axis, among other factors, influences the 
metabolic system. These data lend further support to the hypothesis that the 
relationship between depression and anxiety disorders and CVD is mediated by 
elevated basal cortisol concentrations and lower circadian cortisol variability. 
 In the last study (chapter 6), genetic variation of the C-reactive protein (CRP) 
gene was used as an instrument to investigate associations between plasma CRP and 
saliva cortisol, by using a Mendelian randomization design, in patients with depression 
and anxiety disorders. In this study, we showed that genetic variants in the CRP gene 
were associated not only with higher plasma CRP levels but also with lower salivary 
cortisol levels after awakening, in basal, non-inflammatory conditions. This suggests 
that CRP metabolism and cortisol release during the awakening response are closely 
linked. We proposed a role for the effects of CRP on cortisol in maintaining 
physiological homeostasis and mediating risks of and protection from diseases, such 
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as depression and anxiety disorders. Furthermore, this study extended previous 
research by showing that the Mendelian randomization design might be a fruitful 
approach studying potential causality of associations between a biomarker and a 
psychiatric disorder. 
 
General discussion 
 
The results of the studies presented in this thesis extend the literature on HPA axis 
dysfunction in several ways. Most important, we used a different approach than 
commonly used in this area of research. Not the clinical picture (diagnosis or 
dimension) was central, but cortisol levels were used as starting point in our studies. 
We redefined the phenotype, related to differences in cortisol levels, e.g., hyper- and 
hypocortisolism. We showed that a dimensional clinical phenotype might be additive 
to the DSM-IV classification, for understanding underlying HPA axis dysfunctions. 
Furthermore, we hypothesized that differences in HPA axis activity, e.g. hyper- versus 
hypoactivity, might be a consequence of a sequence in time in chronic stress 
conditions. Additionally, we provided evidence that HPA axis dysregulation is 
associated with the metabolic and immune system in depression and anxiety disorders. 
In the following parts of the general discussion of this thesis these issues will be 
discussed in more detail.  
 
HPA axis activity: from hyper- to hypoactivity? 
The main conclusion of this thesis is that chronic stress might lead to two states of 
dysregulation of the HPA axis (chapter 3 and 4): either a hyperactive or a hypoactive 
HPA axis, associated with, respectively hyper- and hypocortisolism. How can these 
seemingly contradictory effects of chronic stress be explained? Are they distinct 
entities or part of a sequence in time?  
A recent meta-analysis showed that in the first period after the onset of stress 
cortisol levels are elevated (phase 1: acute and intermediate stress), while later on the 
levels are below normal (phase 2: chronic stress).12 A time dependent pattern of this 
nature is consistent with theories advanced by several researchers on the association 
between chronicity and hyper- and hypocortisolism.13-15 Hypercortisolism and 
hypocortisolism might not be contradictionary, but might simply reflect different time 
points during the stress process. Unfortunately, our study, as well as most other 
studies included in the meta-analysis, had a cross-sectional design. But although this 
design precludes statements on causation and timing, our finding of an inverted U-
shaped association between cortisol concentrations in the first hour after awakening 
and the MASQ dimensions is consistent with the idea that depression and anxiety 
disorders initially lead to enhanced HPA axis activity, resulting in higher morning 
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cortisol levels. Increasing severity might eventually lead to an (over)adjustment of the 
HPA axis by means of (1) the down-regulation of specific receptors on different levels 
of the axis (hypothalamus, pituitary, adrenals, target cells), (2) reduced biosynthesis or 
depletion at several levels of the HPA axis (CRF, ACTH, cortisol) and/or (3) 
increased negative feedback sensitivity to glucocorticoids, all together contributing to 
lower morning cortisol levels.14;15 Previous studies provided evidence that an enhanced 
HPA axis function adapts to chronic and/or severe stress by subsequent down-
regulation of  receptors, resulting in a blunted CAR.16;17 Longitudinal studies are better 
equipped than the studies presented in this thesis to answer questions such as: At 
what point in time does the HPA axis begin to decline from its peak? When does it 
drop below a person’s baseline? At what point does it reach the asymptote and stop 
declining? In short, the next wave of studies will need to discern the shape of the time 
function, and they can only be done using prospective longitudinal designs with 
repeated assessments of HPA axis functioning.  
 A theoretical perspective on hyper- and hypocortisolism is also captured by the 
concept of ‘allostatic load’ as posited by McEwen.18 This theory describes an 
individual’s physiological response to stress. Diverse physiological systems 
accommodate to changing conditions in an effort to achieve stability by change 
(allostasis), and are thus protective in terms of adaptation. However, over time, this 
accommodation may produce allostatic load, which refers to the wear and tear that the 
body experiences due to repeated cycles of allostasis as well as the insufficient turning-
on and shutting off of these responses. As so, chronic hyper- or hypoactivity of the 
stress system may have adverse effects on the organism.  
According to McEwen, al least four types of allostatic load can be identified: (1) 
repeated challenges, (2) failure to habituate with repeated challenges; (3) failure to shut 
off the response after the challenge is past, and (4) failure to mount an adequate 
response (see figure 1). The first three types are all associated with a hyperactive HPA 
axis accompanied by higher cortisol levels, which might lead to manifestations of the 
metabolic syndrome (insulin resistance, dyslipidaemia, hypertension, hyper-
coagulability, and visceral obesity).19 Type 4 is characterized by a hypoactive HPA axis 
associated with a lower than needed cortisol, leading to compensatory hyperactivity of 
the other mediators, e.g. increased levels of cytokines that are normally counter-
regulated by cortisol.19 However, in this theory no explicit hypotheses are formulated 
on chronological relatedness between type 1 to 3 on one hand and type 4 on the other 
hand. Presumably, when types 1 to 3 are long lasting, it might eventually develop into 
a type 4 state of allostatic load.  
In summary, homeostatic systems exert their effects in an inverse, U-type dose 
response relationship. Eustasis is in the middle, optimal range of the curve. Eustasis is 
the case in healthy persons, but also as intermediate phase switching form a hyper- to 
Chapter 7 
 111 
hypofunction of the homeostatic system. Suboptimal effects may be on either side of 
the curve and can lead to suboptimal adaptation, which may be harmful to the 
organism in the short or long term.  Both hypofunction and hyperfunction of the 
homeostatic systems have multiple aversive effects. With regard to the HPA axis, a 
hyper- and hypoactive state, associated with, respectively hyper- and hypocortisolism, 
refer to both suboptimal sides of the homeostatic stress system.20 We assume that 
those states are not distinct entities, but part of a sequence in time leading from a 
hyperactive (phase 1: acute and intermediate stress) via a normoactive state to a 
hypoactive state (phase 2: chronic stress) when stress holds on.  
 
 
 
In the next paragraphs, we will further discuss the relationships between the two 
forms of dysregulations of the HPA axis, i.e., hypercortisolism (phase 1) and 
hypocortisolism (phase 2), and how they relate to clinical phenotypes and parameters 
of the metabolic and immune system in patients suffering from depression and/or 
anxiety disorders (see figure 2 for a summary).  
Figure 1. Four types of allostatic Load 
The top panel illustrates the normal 
allostatic response, in which a 
response is initiated by a stressor, 
sustained for an appropriate interval, 
and then turned off. The remaining 
panels illustrate four conditions that 
lead to allostatic load: 1) Repeated 
"hits" from multiple novel stressors; 2) 
Lack of adaptation; 3) Prolonged 
response due to delayed shut down; 
and 4) inadequate response that leads 
to compensatory hyperactivity of other 
mediators: e.g., inadequate secretion 
of cortisol, resulting in increased 
levels of cytokines that are normally 
counter-regulated by cortisol.. 
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Figure 2. Schematic summary of this thesis: Associations between, respectively hypercortisolism (right side of 
figure: phase 1) and hypocortisolism (left side of figure: phase 2) and phenotypic characteristics, metabolic and 
immune factors in depression and anxiety disorders. Associations relating to a hyperactive hypothalamus-
pituitary-adrenal axis are depicted. HPA = hypothalamus-pituitary-adrenal axis; CAR = cortisol awakening 
response; CRP = C-reactive protein. 
 
Cortisol and the clinical phenotype 
We used cortisol concentrations, by assessing salivary cortisol day curves, as core 
parameters by which we attempted to redefine the phenotype of psychopathology. We 
showed that hypercortisolism and hypocortisolism are associated with specific clinical 
phenotypes. Differences in cortisol levels were found between patients suffering from 
DSM-IV depressive disorder and controls. In addition dimensional phenotypes 
provided additional information on linear and nonlinear aspects of cortisol dynamics. 
The results of our studies on this topic will be discussed in the next two paragraphs. 
 
Hypercortisolism and the clinical phenotype 
Higher cortisol concentrations were found in patients with depression according to 
DSM-IV criteria compared to controls during the diurnal decline, which is in line with 
previous studies that showed elevated basal cortisol levels in depressive patients 
during the day.21-23 A diminished negative feedback or a higher hypothalamic drive 
might be responsible for these higher levels. As described in chapter 4, we supposed 
that using the tripartite dimensional model as an alternative approach to phenotyping 
might provide additional information about HPA axis dysregulations. And indeed, 
regarding the diurnal cortisol decline, cortisol showed a linear relationship with the 
anhedonic depression and general distress dimensions of the tripartite model, 
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indicating that higher cortisol concentrations are associated with higher dimensional 
scores. The linear association between the two tripartite dimensions and cortisol 
concentrations during the diurnal decline confirms previous findings in which more 
severe psychopathology was related to higher cortisol concentrations.24  
In our study on cortisol and the dimensions of the tripartite model, none of the 
cortisol measures were associated with the anxious arousal dimension. This might 
indicate that affective dimensions, e.g., anhedonic depression and general distress, are 
more closely related to HPA axis dysfunction than arousal dimensions. This is in line 
with previous studies on anxiety disorders, which are characterized by arousal 
symptoms, showing that basal cortisol was unaltered as compared to controls.25-32 
Otherwise, arousal measures, compared to affective measures, might be more subject 
to temporary fluctuations depending on momentary stressors.  
In summary, we replicated previous findings of elevated diurnal cortisol levels in 
patients with a depressive disorder, although this is not a consistent finding in the 
literature. In addition, we demonstrated linear associations between diurnal cortisol 
levels and two dimensions of the tripartite model, suggesting that increasing severity 
(increase in dimensional scores) is initially related to increasing cortisol levels.  
 
Hypocortisolism and the clinical phenotype 
We showed hypocortisolism in depressed patients with comorbid anxiety disorders. 
Lower cortisol concentrations after DEX intake were found in our sample of 
depressed patients with comorbidity, indicating increased negative feedback sensitivity 
in this subgroup of depressed patients (chapter 3). Increased sensitivity to 
glucocorticoid negative feedback is one of the most common features of 
hypocortisolism.15 As stated before, disease progression and increasing severity might 
lead to a (over)adjustment, and consequently to a hypoactivity of the HPA axis. This 
might be the case in depressed patients with comorbid anxiety disorders. Comorbidity 
of depression and anxiety disorders is widely understood to be associated with 
increased severity, persistence, chronicity, and functional impairment.33 The 
persistence is illustrated by the relatively early age of onset of the pathophysiology in 
this patient group, who mostly starts with an anxiety disorder later to be accompanied 
by depression.34 Furthermore, depressive patients with comorbid anxiety disorders 
often are characterized by more severe psychopathology.35 
 In addition, in our studies associations were found between hypocortisolism and 
some dimensional phenotypes. Cortisol concentrations after awakening showed a 
nonlinear relationship with the anhedonic depression and general distress dimension 
of the tripartite model, indicating an inverted U-shaped association (chapter 4). Our 
finding of an inverted U-shaped association between cortisol concentrations in the 
first hour after awakening and tripartite dimensions might suggest that depression and 
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anxiety initially may lead to enhanced HPA axis activity, resulting in higher morning 
cortisol levels (phase 1). Disease progression and increasing severity may eventually 
lead to a down-regulation of the GR receptors, resulting in lower morning cortisol 
levels (phase 2).14;15  
In summary, our studies strengthen the hypothesis that ongoing stress and/or an 
increase in severity of psychopathology leads to a down-regulation of the GR 
receptors accompanied by an increased negative feedback mechanism and 
hypocortisolism.  
 
Conclusion 
We provided evidence for hypercortisolism during the diurnal decline in depressed 
patients. Furthermore, we found linear associations between cortisol and severity of 
psychopathology (e.g., indicated by dimensional scores). Increasing severity is 
associated with higher cortisol levels during the diurnal decline. On the other hand, we 
found hypocortisolism in a subgroup of depressed patients with comorbid anxiety 
disorders. Lower cortisol levels were also found in depressed/anxious patients who 
score extremely high (upper tertile) on the anhedonic depression and general distress 
dimensions of the tripartite model. This suggests that a further increase in severity, 
might initially lead hyperactivity of the HPA axis, but on the longer term switch to a 
hypoactivity of the HPA axis. The non-linear associations during CAR versus the 
linear associations during the diurnal decline support the idea that the cortisol release 
during the CAR and during the diurnal decline are under distinct regulatory influences 
resulting in different kinds of associations (i.e., linear and non-linear) between 
tripartite dimensions and cortisol concentrations.36-38 
 
Cortisol and the metabolic system 
Cortisol, the final hormone effector of the HPA axis, potently affects the overall body 
metabolism, exerting a broad spectrum of primarily catabolic effects as part of a 
generalized effort to increase the availability of energy sources when needed in a stress 
situation. In addition to their direct catabolic actions, cortisol also antagonizes 
anabolic actions of thyroid hormones, insulin, and sex steroids on their target tissues. 
This stress-related shift of metabolism from an anabolic to a catabolic state normally 
reverses upon retraction of the posed stressor. However, chronic stress might 
dysregulate the HPA axis and consequently the metabolic system. 
 
Hypercortisolism and the metabolic system 
In chapter 5, we provided evidence that hypercortisolism (and lower circadian 
cortisol variability) is associated with detrimental lipid metabolism, one of the features 
of the metabolic syndrome, in patients with depression and/or anxiety disorders. 
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Hypercortisolism contributes to insulin resistance, resulting in increased lipolysis by 
inhibition of lipoprotein lipase. Increased lipolysis results in increased serum levels of 
LDL cholesterol, total cholesterol, and triglycerides and decreased serum levels of 
HDL cholesterol 39. Our findings on the association between elevated cortisol levels 
and dyslipidaemia in our patient group is in line with a study that showed associations 
between high 24h urinary cortisol levels and metabolic syndrome (which includes 
dyslipidaemia) in elderly depressed patients with a mean age 74.40 Our findings suggest 
that the positive association between cortisol and dyslipidaemia is not limited to 
elderly depressed patients. In other studies, patients after organ transplantation 
showed associations between glucocorticoid administration and hyperlipidaemia.41-43  
 Metabolic syndrome is characterized by dyslipidaemia, as well as by visceral 
obesity, insulin resistance, and hypertension. The metabolic syndrome is a clustering 
of risk factors for cardiovascular diseases.44 Epidemiologic studies evaluating the 
association between depression and metabolic syndrome suggest that a bidirectional 
relationship exists between these conditions.45 Results from clinical studies evaluating 
depression and metabolic syndrome provide a more detailed estimate of the risk as 
well as mediational factors and consequences associated with these two conditions 45. 
However, not all depressed patients show aspects of the metabolic syndrome. We 
hypothesize that an association between the metabolic syndrome and depression 
predominantly exists in patients with a hypercortisolemic depression, because 
chronically elevated cortisol, as explained above, contributes to the most important 
aspects of the metabolic syndrome, including insulin resistance, visceral obesity, and 
dyslipidaemia.  As far as we know, only one study examined the metabolic syndrome 
in hypercortisolemic depression. This study suggests a synergistic relationship between 
depression in elderly, cortisol and metabolic syndrome.40 No studies were done on 
metabolic changes in hypocortisolemic depression.  
In summary, chronic exposure to stress, leading to HPA hyperactivity, might be 
potentially damaging because the prolonged glucocorticoid action causes 
hyperglycemia, dyslipidaemia (increased triglycerides, decreased HDL cholesterol), and 
hypertension, which all are manifestations of the metabolic syndrome.46 We provided 
evidence that hypercortisolism is associated with dyslipidaemia in patients with 
depression and anxiety disorders. Therefore, hypercortisolism might partly explain the 
increased risk of CVD through its effects on lipoprotein metabolism.  
 
Hypocortisolism and the metabolic system 
Knowledge concerning the metabolic effects of cortisol is primarily based on studies 
in which varying amounts of cortisol or synthetic glucocorticoids have been given, or 
on studies of patients with endogeneous hypersecretion, whereas little is known about 
the metabolic effects of hypocortisolism. In general, patients with Addison's disease 
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show hypocortisolism and present clinically with weight loss, muscular weakness, and 
fatigue and a tendency to hypoglycemia, but there is a lack of controlled studies in this 
field on the nature of the alterations. Therefore, the effects of low cortisol levels on 
metabolism remain uncertain in these patients. In a recent study, the metabolic effects 
of acute cortisol withdrawal were investigated on glucose, lipid, and amino acid 
metabolism in patients with adrenocortical failure. It was shown that cortisol 
withdrawal increases insulin sensitivity.47 This finding is in line with previous studies 
showing that the opposite, insulin resistance, is related to short-term cortisol excess. It 
is shown that cortisol promotes lipolysis, rendering it possible that increased levels of 
free fatty acids in the circulation may contribute to the observed insulin resistance.48 
In the study of Christiansen et al. no changes were observed in free fatty acids levels or 
lipid oxidation rates, suggesting that the observed increase in insulin sensitivity is 
directly related to hypocortisolism, and not to changes in lipid metabolism.47 
However, this study was on the metabolic effects after acute cortisol withdrawal, so 
not much is known about the relationship between longstanding hypocortisolism and 
the metabolic system, including lipid metabolism. 
 
Conclusion 
 A lot of research has been done on the associations between elevated cortisol levels 
and (lipid) metabolism, but not much is known about the effects of decreased cortisol 
levels on the metabolic system. We provided evidence that dyslipidaemia, which is one 
of the characteristics of the metabolic syndrome, is associated with higher cortisol 
levels in depressed and anxious patients. Our data lend support to the hypothesis that 
the relationship between depression and CVD is partly mediated by HPA axis 
perturbations. However, as is shown before, another part of this patient group might 
be characterized by low cortisol levels. Not much is known yet about associations 
between hypocortisolism en lipid metabolism. Therefore, more research needs to be 
done on this topic. 
 
Cortisol and the immune system 
The immune system is typically divided into two categories - innate and adaptive -
although these distinctions are not mutually exclusive. Innate immunity refers to 
nonspecific defense mechanisms that come into play immediately or within hours of 
an antigen's appearance in the body. These mechanisms include physical barriers such 
as skin, chemicals in the blood, and immune system cells that attack foreign cells in 
the body. The innate immune response is activated by chemical properties of the 
antigen. Adaptive immunity refers to antigen-specific immune response. The adaptive 
immune response is more complex than the innate. The antigen first must be 
processed and recognized. Once an antigen has been recognized, the adaptive immune 
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system creates an army of immune cells specifically designed to attack that antigen. 
Adaptive immunity also includes a "memory" that makes future responses against a 
specific antigen more efficient.  
The immune system is influenced by changes in HPA axis activity There is a tight 
and reciprocal relationship between the circulating pro-inflammatory cytokines and 
the HPA axis, an alliance which subserves the preservation of the threatened body 
homeostasis under conditions of stress and systemic inflammation. The HPA axis has 
profound inhibitory effects upon the inflammatory response, primarily due to the 
actions of the glucocorticoids, which inhibit virtually all the mobilized components of 
the innate and adaptive immune system. This action of corticosteroids is thought to 
prevent extensive damage to the body potentially inflicted by uncontrolled 
inflammatory and immune activation.49;50  
 
Hypercortisolism and the immune system 
Cortisol is the most potent anti-inflammatory hormone in the body. It acts on the 
immune system by both suppressing and stimulating pro- and anti-inflammatory 
mediators respectively.51 While cortisol promotes T helper 2 (Th2) development, for 
example by enhancing interleukin 4 (IL-4) and interleukin 10 (IL-10) secretion by 
macrophages,52 it inhibits inflammatory responses and suppresses the production and 
release of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-α), 
interleukin 1 (IL-1), and interleukin 6 (IL-6).53 During stress the immune system 
becomes activated, resulting in a release of cytokines.20 An important role of cortisol 
during stress is to suppress the production and activity of pro-inflammatory cytokines, 
thus restraining the inflammatory reaction and preventing tissue destruction.18 The 
inhibitory effect of cortisol on the production of pro-inflammatory cytokines is clearly 
depicted in the inverse rhythm of cytokine secretion in relation to the plasma cortisol 
levels that is documented under both basal conditions (circadian rhythm of inhibition) 
and inflammatory action.54;55 Accordingly, stress-induced increases in cortisol levels 
prevent bodily responses from overshooting by its immunosuppressive effects. 
However, in case of chronic stress associated with hypercortisolism, there is an 
immunosuppression at virtually every level of the immune and inflammatory 
responses, including during activation of the innate immune response and in both 
cellular and humeral acquired immune responses. Therefore, hypercortisolism leads to 
an enhanced susceptibility to infection.54;56 
Besides the immunosuppressive effect, cortisol also synergistically stimulates the 
acute phase response, in combination with IL-6, which includes the production of 
CRP. CRP increases the ability of blood to coagulate and decreases fibrinolysis and by 
their pro-atherosis action have a negative effect on longevity.57 Not much is known 
about the direct pathway from CRP to cortisol release. We assume a bidirectional 
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relationship between CRP and cortisol to play a role in maintaining the physiological 
homeostasis. Therefore, a negative feedback mechanism between CRP and cortisol 
might be present. Our study on this issue will be discussed in the next paragraph. 
 
Hypocortisolism and the immune system 
Hypocortisolism, as is observed in patients suffering from chronic or severe stress-
related disorders, may result in an overactivity of the immune system in terms of 
increased inflammatory responses due to the impaired suppressive effects of low 
cortisol. This assumption is supported by studies reporting elevated levels of pro-
inflammatory cytokines in stress-related disorders characterized by hypocortisolism, 
e.g., chronic fatigue syndrome and fibromyalgia.58-60  
In chapter 6, we tried to elucidate the relationship between plasma CRP levels and 
basal salivary cortisol levels over the day under non-inflammatory conditions. We 
showed that genetic variants in the CRP gene are associated not only with higher 
plasma CRP levels but also with lower salivary cortisol levels after awakening. In 
general, stressful and pro-inflammatory conditions, such as acute infections, may 
increase both CRP and cortisol levels, due to activation of the immune system and 
HPA axis. But, previous studies showed that in chronic inflammatory conditions, such 
as rheumatoid arthritis and Sjögren’s syndrome,61-63 cortisol levels were not elevated, 
despite the presence of chronic high circulating inflammatory cytokine and CRP 
levels. This phenomenon was referred to as an ‘inadequate’ low cortisol secretion 
relative to the chronic inflammatory status.61;63 It could be hypothesized that a chronic 
pro-inflammatory state with high CRP levels ultimately results in adaptation of the 
HPA axis, by negative feedback mechanisms, leading to lower cortisol levels. In other 
words, CRP effects on cortisol may play a role in maintaining the stress homeostasis. 
However, in contrast with the direct effects of CRP polymorphisms on CRP levels, 
the mechanism of the effect on cortisol levels likely involves a much more complex 
network of endogenous interactions that include, among others, cytokines. 
 
Conclusion 
To summarize, the connections between the HPA axis and the immune system 
provide a finely tuned regulatory system required for health. Chronic hypercortisolism 
leads to an overall suppression of immune responses and to an enhanced susceptibility 
to infection, whereas hypocortisolism is associated with an enhanced susceptibility to 
inflammation.55 In addition, we provided evidence that genetic variants in the CRP 
gene that are associated with higher plasma CRP levels, are also associated with lower 
salivary cortisol levels after awakening, in basal, non-inflammatory conditions, 
suggesting the presence of a negative feedback mechanism between CRP and cortisol 
to maintain homeostasis. 
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Strengths and limitations 
A major strength of our studies is that they departed from the level of the stress 
system where the stress reaction starts, namely the HPA axis. By using this approach, 
we were able to avoid the problems that are related to the lack of validity of the 
categorical DSM-IV diagnoses, as described before.  
Another advantage of our approach of taking the HPA axis as starting point is that 
we were able to investigate the nonlinear aspect of the HPA system, which 
characterizes all homeostatic systems. Suboptimal function (i.e., hyper- versus 
hypofunction) is observed at both sides of a homeostatic system, e.g. the HPA axis. 
And indeed, part of the patients with depression and anxiety disorders, are 
characterized by hypercortisolism (i.e., hyperfunction), and part by hypocortisolism 
(i.e., hypofunction). Both dysfunctional states are assumed to differ in phenotypic 
presentation, and in their effects on metabolic and immune parameters, as is shown in 
our studies. 
Furthermore, saliva sampling was used to assess cortisol levels over the day. 
Cortisol levels measured in saliva provide a valid and reliable correlate of serum or 
plasma cortisol concentrations. Cortisol in saliva is 100% unbound and biologically 
active.64 The available literature clearly suggests that despite lower concentration in 
saliva, saliva cortisol is even closer correlated with the free cortisol fraction in serum 
compared to total serum cortisol.65  
In addition, measurement of cortisol in saliva has many advantages over 
determination from blood samples. Saliva sampling is non-invasive and therefore not 
painful (avoiding the risk of stress-induced modulation of cortisol levels), it does not 
require trained medical personnel and can be repeated frequently. In addition, the 
collected samples need no special treatment and are stable at room temperature for up 
to 7 days. These advantages mean that samples can reliably be taken in a normal 
ambulatory setting, for example the subject's own home, as they go about their routine 
activities.  
An additional strength of our studies is the collection of multiple salivary samples 
over the day on two consecutive, non-working days, to allow controlling for day to 
day variations. The cortisol curve of a single day is determined by situational factors 
and – to a smaller extent – by trait factors. Therefore, to reduce measurement errors 
and the effects of day-to-day variations,66 subjects were asked to provide saliva 
samples during two consecutive non-working days. Non-working days were chosen to 
reduce confounding, because most patients were non-working due to their illness. 
Another important advantage is that the subjects of our studies were free of 
psychotropic medication. There is evidence that this kind of medication might 
influence HPA axis function.67  
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Last but not least, several biological and genetic markers were assessed (i.e., 
lipids/lipoproteins, indices of adiposity, acute phase reactants, and CRP 
polymorphisms), which enabled us to investigate associations of HPA axis 
dysfunctions with parameters of the metabolic and immune system.  
In the last study, genetic variation of the CRP gene was used as an instrument to 
investigate associations between CRP and cortisol by using the Mendelian 
randomization design. Instrumental variables, such as genetic variants, can be used to 
strengthen causal inferences in non-experimental situations. Alleles are generally 
unrelated to confounding factors, in particular, socioeconomic position and life style 
factors that distort the interpretations of observational epidemiology. Furthermore, 
disease processes do not alter genotypes and therefore associations between the 
genotype and disease outcomes cannot be affected by reverse causality. Unlike 
randomized controlled trials, Mendelian randomization studies can be conducted in a 
representative population without the need for exclusion criteria. It is important to 
note that the aim of Mendelian randomization studies is not to identify functional 
genes for an outcome, but the approach depends on knowing about the function of 
the genes before undertaking the study.68;69 
However, the findings of this thesis also need to be valued in the light of some 
methodological limitations. As discussed before, a major limitation is the cross-
sectional design of our studies, which precludes conclusions about changes in HPA 
axis dysfunctions over time. Longitudinal studies are needed to answer this aspect of 
HPA axis function.  
Secondly, the sample size was relatively small, which might have lead to a lack of 
statistical power. Nevertheless, despite the relatively small sample size we were able to 
detect several significant associations between cortisol and phenotypic, metabolic and 
immune parameters.  
Thirdly, subjects sampled saliva at home without electronic monitoring. Some 
precautions were taken to avoid non-compliance. For instance, subjects were asked to 
register the times they actually sampled in order to be able to do a limited check 
whether subjects sampled at the required times. Furthermore, subjects received the 
explicit instruction to lay the first salivette for sampling next to their bed, so minimal 
time is lost between awaking and the first sampling. No evidence was present for 
differences in compliance between groups (for instance, depressed patients and 
healthy controls), but some influence of non-compliance might still have been present.  
Fourthly, previous studies found larger differences in HPA axis measures in 
psychiatric in-patients with more severe forms of psychopathology compared to 
controls. We included outpatients, and not inpatients with severe psychopathology, 
and this may have reduced the sensitivity to detect HPA axis dysfunctions.  
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Fifthly, no valid, world-wide used dimensional model of depression and anxiety 
disorders is yet available. Therefore, for the study in this thesis, we chose the tripartite 
model of anxiety and depression, because it is the most broadly accepted in adult 
psychiatry.70-72 Clark and Watson’s tripartite model is designed to handle the high 
comorbidity rates of depressive and anxiety disorders73 by taking account of both 
overlapping and distinct features of anxiety and depression. An additional advantage 
of the tripartite model is the availability of a validated questionaire that assesses the 
three dimensions of the model, the so called Mood and Anxiety Symptom 
Questionnaire (MASQ).74-76  
 
Practical advices for future cortisol research 
Salivary cortisol has emerged as an easy-to-collect, relatively inexpensive, biological 
marker of stress. However, circulating cortisol is highly variable and is responsive to a 
wide range of factors that should be considered when incorporating this measure in 
research. Two advantages that salivary cortisol has over plasma cortisol are that 
samples can be collected through relatively noninvasive techniques and that they can 
be timed without depending on the availability of a laboratory or health care 
professional. Based on the experiences during the studies presented in this thesis, we 
provide some advices for salivary cortisol sampling in future research.   
1. To control for the effects of circadian and diurnal rhythms, the time of day 
samples are collected should be standardized. Ideally, samples are collected at 
fixed time points during the day for all subjects. The number of samples obtained 
must also be established. More samples provide more information on individual 
fluctuations. We think 3 à 4 samples within the first hour after awakening are 
needed to assess the CAR followed by 4 samples during the rest op the day with 
time intervals of 3-4 h to assess the underlying diurnal profile, e.g., at 11:00h, 
15:00h, 19:00h and 23:00h.77;78  
2. Regarding the waking modus. In a previous study it was shown that CAR did not 
differ on days were subjects woke up spontaneously or used the alarm clock 77. 
We advice, however, to use the spontaneous waking modus in combination with 
an alarm clock. Sampling after spontaneous awakening should be the primary 
instruction, because, patients with depression and/or anxiety disorders are often 
early awakeners and might therefore wake up before the alarm clock is set. In 
addition, an alarm clock should be set, for instance at 7:00h, because if subjects 
tend to sleep late, they often doze for some time through which the CAR might 
be missed. 
3. Saliva samples should be collected on more than one day, in order to be able to 
test the reliability of sampling and/or the interindividual stability.  The CAR of a 
single day is determined to a great extent by situational factors and only for a 
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small proportion by trait factors, and from two to six days is necessary to achieve 
reliable trait measures, since state factors bias data from a single day. The total 
area under the curve (AUCt) is a good choice for assessing hyper- and 
hypocortisolism. Sufficient reliability was observed for the AUCt after 2 days.66 
Therefore, to reduce measurement error and the effects of day-to-day variation, 
subjects should be asked to provide saliva samples on at least two consecutive 
days.  
4. The materials and techniques used to collect samples may influence the accuracy 
of testing. A common way of obtaining saliva for analysis involves the use of the 
commercially available Salivatte (Saarsredt). The Salivette looks like a 2-inch 
cotton dental roll and is packed in a plastic test-tube-like containers. Subjects are 
instructed to chew or mouth the Salivette for approximately 30 to 45 seconds. In 
a recent study it was shown that that salivary cortisol measurement with Salivettes 
is a reliable prediction method of total and calculated free serum levels. It is a 
convenient method for saliva collection, handling a laboratory processing.79 
Although tasteless, the Salivette has a consistency that some subjects find 
unpalatable. Another strategy to assure the collection of adequate samples is to 
use salivary stimulants, such as flavored drink crystals or sugarless gum. However, 
salivary stimulants should be used with caution. Although the rate of salivary flow 
does not affect the cortisol levels, salivary stimulants may alter salivary pH, 
causing an elevation is the cortisol assay.80   
5. Samples should be collected either on working days or on non-working days for 
both the cases and the controls. Anticipation of the working day is associated with 
an enhanced cortisol response.81-83 In psychiatric samples, a considerable number 
of patients are known to be non-working. Therefore, it is preferable in psychiatric 
studies to sample on non-working days for the sake of comparability between 
patients and healthy controls. 
6. Ingestion of food should be avoided 30 min prior to sampling as it increases the 
salivary cortisol concentrations.84;85 
7. To ensure that samples are collected in a consistent, standardized manner, 
protocols for research teams should be developed, in order to make the outcomes 
of different studies comparable. 
8. Patients treated with antidepressants should be excluded, for it is known that 
antidepressants influence the HPA axis regulation via up-regulation of MR and 
GR receptor function and by restoration of the disturbed feedback control.67 
9. Besides stress, the HPA axis is influenced by many situational factors. In a recent 
study on confounding factors of salivary cortisol indicators in a large sample 
without psychopathology it was shown that sociodemographic variables (gender, 
age), sampling factors (awakening time, working versus non-working day, 
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sampling month, sleep duration) and health indicators (smoking, physical activity, 
cardiovascular disease) influence different features of salivary cortisol levels. 
Smoking had the most consistent effect on cortisol levels. These factors should be 
considered in psychoneuroendocrinology research and assessed in an accurate and 
systematic way.86 In a sample size of about 50-100 subjects, one should match the 
groups under study on age and gender and adjust for smoking, sampling month 
and sleep duration. Subject should be asked to abstain from heavy physical 
exercise on the days of sampling and patients with somatic diseases that influence 
the HPA axis, e.g. cardiovascular diseases, should be excluded.  
10. Finally, prospective studies of cortisol sampling are needed in order to be able to 
investigate changes in HPA axis function over time, for instance in circumstances 
of ongoing stress.  
 
Clinical implications 
The DSM-IV is a diagnostic system that describes and lists the currently recognized 
psychiatric disorders and the criteria for diagnosing them. Nearly two decades after 
the release of the current edition, DSM-IV, the fifth edition of DSM (DSM-V) is 
planned for publication around 2012. Despite the enormous advantages represented 
in the DSM-IV, psychiatric diagnosing remains problematic. The principal reason is 
that our present understanding of brain and behavior, and, therefore, of 
pathophysiology of mental illnesses is still in a very early stage and etiology-based 
diagnoses are scarcely possible. For purposes of communication, it is important to 
maintain the best classification system that we have; at the same time we must guard 
against reifying provisional diagnoses, thus inhibiting scientific progress. The human 
brain is the most challenging object of study in the history of human science, and 
illnesses termed ‘psychiatric disorders’ represent dysfunctions of the highest 
integrative functions of the brain including cognition, emotional regulation, and 
executive function. It is timely to ask whether neuroscience has progressed to a point 
that the next DSM-version can usefully incorporate information about brain structure 
and function. Genetic, anatomic and biological markers might enhance diagnostic 
homogeneity. If, however, the lumping and splitting of symptoms that gave rise to the 
current classification was in error, then the search of biological correlates of these 
disorders will not prove to be fruitful. Instead, one should create circumstances in 
which information from genetics, cognitive neuroscience, brain imaging, and animal 
studies can contribute to defining the clinical phenotype.87  
One way in which neuroscience could contribute to the development of better 
diagnostic criteria without prematurely disrupting the current relatively reliable but 
imperfect (because of their limited validity) clinical diagnoses is through the creation 
of experimental diagnostic criteria for research purpose that could shadow the 
Summary and disussion 
 124 
‘official’ criteria in the DSM-V. Experimental approaches towards a novel 
classification of mental disorders could take different forms, depending on the 
situation: 1) dimensional approaches; 2) the identification of clinical significant 
symptom clusters for which there are compelling hypotheses about underlying neural 
circuits; and 3) the abandonment of fine-scale splitting of disorders to yield to larger 
‘spectrum’ disorders, the constituents of which are presumed to share 
pathophysiological features.87 Furthermore, as we showed in this thesis, starting at the 
level were the stress reaction starts, i.e. the HPA axis, might also contribute to a better 
redefinition of the clinical phenotype.  
In summary, we demonstrated that a dimensional approach is able to reveal the 
nonlinear aspects to HPA axis function. In addition, we propose that differentiation 
between hyper- and hypoactive functional states of the HPA axis, might contribute to 
a better redefining of the clinical phenotype and to new insights and developments in 
pharmacological treatment. Furthermore, we propose it to be valuable to collect 
information about the state of the metabolic and immune system in order to get an 
impression of the impact of the stress on the body function and the risk of somatic 
comorbidity.   
 
Future perspectives 
Practicing science is a never ending story; numerous fascinating questions remain to 
be answered. The studies of this thesis provide some new insight in HPA axis 
dysfunctions. This thesis describes new observations and elucidated several facets of 
HPA axis dysfunctions by relating it to phenotypic, metabolic and immune factors 
that might be involved. However, the puzzle is far from being solved.  
We propose that a dimensional approach might be a promising addition to the 
categorical DSM-IV diagnoses, because the results of the studies presented in this 
thesis add evidence that dimensions are predictive for HPA axis dysfunction. There 
are several potential benefits of adding a dimensional approach to the categorical 
DSM system. The most immediate is that it provides quantitative scores, and therefore 
including an indication of severity. Furthermore, it provides a consistent methodology 
of fine-tuned phenotyping across individual patients. Another advantage of a 
dimensional approach is that quantification may help to increase statistical power in 
research. Many more subjects are needed to achieve the same power with a categorical 
diagnosis, than with a dimensional one, under assumption that the underlying 
psychopathology is continuous.  Lastly, a dimensional phenotype is capable to reveal 
the nonlinear aspect of HPA axis dysfunction. This is an important advantage, as we 
showed that patients with depression and/or anxiety are no homogenous group 
neither with respect to underlying HPA axis dysfunctions. Subgroups of 
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hypercortisolemic and hypocortisolemic patients are present, presumably asking for 
different kinds of (pharmacological) treatment.   
Commitment to a dimensional elaboration for depression and anxiety disorders 
(and other psychiatric disorders) could also offer new perspectives on the problem of 
comorbidity, the co-occurrence of two or more distinct disorders. A dimensional 
approach could replace the awkwardness of categorical comorbidity with patient-
specific dimensional profiles.88 However, there is no consensus as yet about a 
uniform, validated, dimensional approach. Consensus is necessary for cross-study 
comparability. Therefore, more work should be done on the refinement of the 
dimensional phenotyping of depression and anxiety disorders. We propose that a 
dimensional model should include specific dimensions that reflect the 
psychopathology of the psychiatric disorders under study, along with two other 
dimensions: one reflecting overall severity of psychopathology (e.g., the general 
distress dimension of the tripartite model) and another reflecting chronicity. As 
motivated in this thesis, severity and chronicity are assumed to determine time-
dependent changes in HPA axis dysfunction, i.e., from initial hyperactivity to 
consequentially hypoactivity. These additional two dimensions are, in our opinion, 
essential components of the clinical phenotype.  
Lastly, we foresee an important role for biomarkers in diagnosing depressive and 
anxious patients. It is reasonable to think that assessment of cortisol levels in an 
individual patient might on the longer term guide our choices for pharmacological and 
psychological treatment. 
 
Concluding remarks 
In this thesis, we provide evidence in research on endophenotypes of 
psychopathology that it is fruitful not to take the clinical picture (diagnosis or 
dimension) central, but the HPA axis as a core stress underlying 
psychopathophysiology in stress-related disorders. Homeostatic systems, including the 
HPA axis, are by nature nonlinear in their function (i.e. dose response effects), with 
suboptimal states of function at both sides of the curve, e.g. hyper- versus 
hypofunction. By taken the HPA axis as starting point, we were able redefine the 
clinical phenotype in relation to both dysfunctional states, i.e., hyper- and 
hypocortisolism. Furthermore, starting with the stress system enabled us to investigate 
the effects of HPA axis dysfunction on the metabolic and immune system. Based on 
the studies presented in this thesis, we hypothesize that the nonlinear aspect of HPA 
axis function reflects different time points during the stress process, from a 
hyperactive HPA axis when the stress begins to, eventually, a hypoactive HPA axis 
when stress holds on. Secondly, we hypothesize that both dysfunctional states of the 
HPA axis, i.e., hyper- and hypocortisolism, differ in their effects on the metabolic and 
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immune system. Ultimately, understanding these mechanisms should result in earlier, 
more specific and therefore more effective interventions, because eventually it is all 
about improving the well-being of our patients. 
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Depressie en angststoornissen zijn psychiatrische stoornissen die gepaard gaan met 
een grote lijdensdruk en een sterke afname van de kwaliteit van leven door 
beperkingen in het functioneren en een hogere sterftekans. Een depressie wordt 
gekenmerkt door een sombere stemming en/of een afname van het plezier kunnen 
hebben in dingen. Daarnaast wordt een depressie gekenmerkt door veranderingen in 
de eetlust, slaapproblemen, vermoeidheid, afname van energie, gevoelens van 
waardeloosheid, cognitieve problemen (twijfelzucht) en gedachten over de dood. In de 
loop van een jaar lijdt bijna 6% van de Nederlandse bevolking aan een depressie. 
 Angststoornissen worden gekenmerkt door overweldigende, irrationele angsten en 
vermijdingsgedrag. De angst gaat vaak gepaard met lichamelijke symptomen zoals 
zweten, hartkloppingen, diarree en duizeligheid. Om die angst zoveel mogelijk te 
voorkomen vermijden mensen met angststoornissen vaak de situaties die angst 
uitlokten. Tot de angststoornissen behoren de volgende ziekten: paniekstoornis, 
sociale angststoornis, posttraumatische stressstoornis, obsessieve-compulsieve 
stoornis, gegeneraliseerde angststoornis en de specifieke fobie. De angststoornissen 
onderscheiden zich van elkaar door de situaties waarin de angst optreedt. In de loop 
van een jaar lijdt ruim 12% van de Nederlandse bevolking aan een angststoornis. 
 Depressie en angststoornissen worden gekenmerkt door een ontregelde reactie op 
stress. Dit is het gevolg van een leven waarin zorgen routine zijn en ingrijpende 
levensgebeurtenissen vaker voorkomen dan normaal. Ook een ongezonde leefwijze 
draagt bij aan het ontstaan van deze ziekten. Niet iedereen die onder zulke 
omstandigheden leeft krijgt een depressie of angststoornis. Erfelijke eigenschappen en 
traumatische gebeurtenissen in de eerste levensjaren (misbruik en emotionele 
verwaarlozing) maken mensen veel 'vatbaarder' voor deze ziekten.  
 De ontregelde reactie op stress blijkt ook uit de afwijkende werking van de 
hypothalamus-hypofyse-bijnierschors as (HPA-as), een in het Nederlands 
ingeburgerde afkorting gebaseerd op de Engelse naam Hypothalamus-Pituitary-
Adrenal axis. De HPA-as is heel belangrijk voor de omgang met stress. Stress activeert 
de HPA-as. Daardoor neemt de afgifte van corticotropin releasing hormone (CRH) in 
de hypothalamus toe. CRH stimuleert de hypofyse tot afgifte van adrenocorticotroop 
hormoon (ACTH). ACTH zet op zijn beurt de bijnieren weer aan tot afgifte van 
cortisol (een belangrijk stresshormoon bij mensen). Cortisol heeft grote invloed op 
andere biologische systemen, zoals het metabole systeem (houdt zich bezig met de 
stofwisseling) en het immuunsysteem (bescherming tegen lichaamsvreemde stoffen en 
ziekten). Het uiteindelijke effect van die invloed is dat we onze reserves zo efficiënt 
mogelijk inzetten om de stress het hoofd te bieden. Doordat cortisol zijn eigen afgifte 
remt dooft onder normale omstandigheden de reactie op stress vanzelf uit. Dit wordt 
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negatieve terugkoppeling genoemd. Heel veel cortisol legt de activiteit van de HPA-as 
zelfs helemaal stil.  
 Hoe meer stress iemand heeft, hoe actiever zijn HPA-as is en hoe meer cortisol uit 
de bijnieren vrijkomt. De concentratie van cortisol kan goed worden gemeten in bloed 
en speeksel. In het onderzoek beschreven in dit proefschrift deden we dat in het 
speeksel onder andere omdat dat voor proefpersonen het minst vervelend is.  
 Hoe de HPA-as op stress reageert, kan worden onderzocht door dit systeem op 
een kunstmatige manier 'uit te dagen' met een zogenaamde ‘challenge’-test. Een 
voorbeeld is de dexamethason (DEX)-CRH test. Dexamethason is een stof dat op het 
lichaam ongeveer dezelfde effecten heeft als cortisol. Zo remt het de HPA-as sterk. In 
de DEX-CRH-test krijgt een proefpersoon 's avonds zoveel dexamethason dat de 
HPA-as de volgende dag vrijwel niet meer actief is. 's Middags krijgt de proefpersoon 
CRH ingespoten. Onder normale omstandigheden zou dat de afgifte van cortisol sterk 
stimuleren. Bij gezonde mensen die zijn 'voorbehandeld'  met dexamethason stijgt de 
afgifte van cortisol echter maar weinig vanwege het remmende effect dat 
dexamethason nog steeds op de HPA-as heeft. Bij depressieve mensen die de DEX-
CRH test ondergaan stijgt de hoeveelheid cortisol in bloed en speeksel wel sterk. Bij 
hen is iets mis met de negatieve terugkoppeling. Hun HPA-as werkt niet naar behoren 
 Het doel van dit proefschrift betrof het vergaren van meer kennis over het 
disfunctioneren van de HPA-as bij patiënten met een depressie en/of angststoornis. 
Gangbaar in de onderzoeken tot nu toe was om eerst een psychiatrische stoornis als 
uitgangspunt te kiezen, bijvoorbeeld depressie, en vervolgens de relatie met de HPA-
as te bestuderen. Deze onderzoeken laten inconsistente en soms zelfs tegenstrijdige 
uitkomsten zien. In geval van depressie, zijn vergeleken met gezonde proefpersonen 
zowel hogere als lagere concentraties cortisol gevonden of geen verschillen. Deze 
inconsistente uitkomsten kunnen samenhangen met de manier waarop psychiatrische 
stoornissen worden geclassificeerd. Dat gebeurt tegenwoordig vrijwel altijd met de 
'Diagnostic and Statistical Manual of Mental Disorders' (DSM)-IV. Een probleem van 
dit systeem is dat veel patiënten meer dan één diagnose hebben (een hoge 
comorbiditeit), terwijl veel klachten een kenmerk zijn van verschillende ziekten (een 
lage specificiteit) ten gevolge van de grote overlap in symptomen tussen depressie en 
angststoornissen.  
 Een alternatieve diagnostische benadering is het gebruik van dimensies (continue 
meetschaal). Een dimensionele benadering heeft een aantal voordelen. Als eerste 
vervangen dimensies de categorische comorbiditeit door het genereren van individuele 
diagnostische profielen op basis van scores per dimensie. Ten tweede kan het gebruik 
van dimensies ons kunnen helpen om meer inzicht te krijgen in de relaties met 
biologische en genetische factoren, omdat ze mogelijk sterker gerelateerd zijn aan 
disfuncties op dit niveau.  
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 In de onderzoeken die beschreven zijn in dit proefschrift hebben we geprobeerd 
de tekortkomingen van de DSM-IV classificatie te vermijden door onze insteek te 
kiezen op het niveau van de HPA-as, omdat dit ons centrale systeem is in de omgang 
met stress. Voor de onderzoeken in dit proefschrift hebben wij cortisol dagcurves 
gemeten en de cortisol afgifte tijdens een 'challenge' test gemeten en gebruikt als 
centrale uitkomstmaten voor de HPA-as functie. Het onderzoek is uitgevoerd bij 
patiënten met een depressie en/of angststoornis en bij gezonde proefpersonen. Met 
behulp van cortisol hebben we geprobeerd om een alternatieve manier van 
diagnosticeren van het klinisch beeld te ontwikkelen. Daarnaast hebben we gekeken 
naar de relatie onderzocht tussen de HPA-as en het metabole en immuunsysteem.  
In hoofdstuk 2 wordt beschreven dat het noodzakelijk is om alternatieve 
manieren van diagnosticeren ontwikkelen om de biologische verstoringen die ten 
grondslag liggen aan psychiatrische stoornissen beter te kunnen begrijpen. Als 
alternatief voor het DSM-IV systeem wordt het gebruik van dimensies voorgesteld. In 
dit hoofdstuk wordt gesteld dat psychiatrische symptomen continu van aard zijn in 
tegenstelling tot de categorische DSM-IV diagnoses. Goede psychologische dimensies 
zijn in staat om afwijkingen in cortisol afgifte te voorspellen. Wij veronderstellen dat 
dimensies dichter bij biologische verstoringen staan dan DSM-IV diagnoses.  
 In het hoofdstuk 3 worden de resultaten beschreven van een onderzoek naar het 
functioneren van de HPA-as bij depressieve patiënten met en zonder comorbide 
angststoornis in vergelijking met gezonde proefpersonen. Er werd gebruik gemaakt 
van de DEX/CRH test. Patiënten met een depressie en een comorbide angststoornis 
lieten een sterkere onderdrukking van cortisol na DEX-inname zien dan de andere 
twee onderzoeksgroepen. De conclusie van dit onderzoek was dat comorbiditeit 
invloed heeft op de HPA-as functie. Voorgaande onderzoeken hielden vaak geen 
rekening met de invloed van comorbiditeit. Daarom kunnen onze bevindingen deels 
een verklaring vormen voor de eerdere inconsistente uitkomsten in onderzoeken naar 
het functioneren van de HPA-as in patiënten met depressie en angststoornissen. 
 In hoofdstuk 4 wordt de uitkomst van een onderzoek gepresenteerd naar de 
relatie tussen cortisolconcentraties en psychologische dimensies bij patiënten met 
depressieve en/of angststoornissen. Er werd gebruik gemaakt van het tripartiete 
dimensionele model van Clark en Watson. Zij onderscheiden in hun model 3 
dimensies: “general distress” (negatief affect), “anhedonic depression” (gebrek aan 
positief affect) en “anxious arousal” (lichamelijke angstsymptomen). Wij vonden 
lineaire en non-lineaire (omgekeerde U-curve) verbanden tussen cortisolconcentraties 
en dimensies. Bij een lineair verband neemt de biologische verstoring (bijv. 
cortisolafgifte) toe als de klachten toenemen. Een non-lineair verband (omgekeerde U-
curve) betekent dat bij toename klachten de biologische verstoring eerst toeneemt 
(hogere cortisol afgifte), maar later afneemt (lagere cortisol afgifte). Non-lineaire 
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verbanden kunnen wel worden aangetoond met dimensies, maar niet met DSM-IV 
diagnoses. De conclusie van ons onderzoek was dat de omgekeerde U-curve wijst op 
een omkering van HPA-as activiteit bij aanhoudende/toenemende klachten. 
Depressieve en angstklachten leiden in eerste instantie leidt tot een hyperactieve HPA-
as (hogere cortisolconcentraties). Een verdere toename van klachten (hogere 
dimensionele scores) kan leiden tot een switch naar een hypoactieve HPA-as (lagere 
cortisolconcentraties), wat gezien kan worden als een (over)aanpassing van de HPA-
as.  
 In hoofdstuk 5 hebben we de relatie tussen de HPA-as en het lipidenmetabolisme 
en overgewicht bestudeerd in patiënten met een depressie en/of angststoornis. 
Bekend is dat een afwijkend lipidenprofiel en overgewicht risicofactoren voor het 
ontwikkelen van hart- en vaatziekten zijn. Wij vonden dat twee uitkomstmaten van 
disfunctie van de HPA-as (verhoogde cortisol afgifte en vlakkere cortisol dagcurve) 
gerelateerd zijn aan een afwijkend lipidenprofiel, maar niet aan overgewicht. Een 
verhoogde cortisolafgifte wijst op een hyperactief stresssysteem en een vlakkere 
cortisolcurve duidt op een gebrek aan flexibiliteit van het stresssysteem. Dit 
onderzoek ondersteunt de hypothese dat de relatie tussen depressie en/of 
angststoornissen met hart- en vaatziekten, onder andere, loopt via een verstoorde 
HPA-as functie.  
 In hoofdstuk 6 wordt een onderzoek besproken waarin een andere 
onderzoeksmethodiek is toegepast, namelijk ‘Mendelian Randomization’. Deze 
methodiek houdt in dat er gebruik wordt gemaakt van genetische verschillen tussen 
mensen. In dit onderzoek hebben we gekeken naar de relatie tussen C-reactief 
proteïne (CRP) en speeksel cortisol. CRP is een eiwit dat in de lever wordt 
geproduceerd als er een ontstekingsproces gaande is in het lichaam. CRP wordt 
daarom vaak gebruikt wordt als maat voor ontsteking. Cortisol, samen met andere 
ontstekingsfactoren, stimuleert de afgifte van CRP. Daarnaast heeft cortisol ook een 
remmend effect op het immuunsysteem. Het samenspel tussen CRP en cortisol wordt 
verondersteld een belangrijke rol te spelen bij de fysiologische homeostase. 
Homeostase is het vermogen van de mens om zijn interne milieu constant te houden, 
ook onder omstandigheden van psychische (bijv. depressie) of lichamelijke (bijv. 
ontsteking) stress. Dit onderzoek laat zien dat CRP een remmende invloed heeft op 
cortisolafgifte, wat gezien kan worden als een negatieve terugkoppeling voor de 
handhaving van de homeostatische balans. 
De resultaten die in dit proefschrift beschreven worden vormen een uitbreiding op 
de reeds bestaande literatuur over de disfunctie van de HPA-as bij depressie en/of 
angststoornissen. De belangrijkste meerwaarde van dit proefschrift is dat we gekozen 
hebben voor aan andere benadering dan meestal wordt gekozen in dit onderzoeksveld. 
Niet het klinische plaatje (de diagnose of het symptoom) stond centraal, maar de 
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cortisolconcentraties zijn gebruikt als uitgangspunt in onze onderzoeken. Wij hebben 
het klinische beeld geherdefinieerd op basis van verschillen in cortisolconcentraties. 
Onze uitkomsten laten zien dat een dimensioneel model toegevoegde waarde heeft 
voor de DSM-IV classificatie, omdat het in staat is non-lineaire verbanden tussen 
psychopathologie (uitgedrukt in dimensionele scores) en cortisol te ontdekken. Op 
basis van deze uitkomst hebben wij de hypothese geformuleerd dat stress is 
geassocieerd met een hyperactiviteit van de HPA-as, maar op termijn, bij 
aanhoudende stress, kan de hyperactiviteit overgaan in een hypoactiviteit van de HPA-
as. Enige bescheidenheid is hier echter op zijn plaats, omdat onze onderzoeken cross-
sectioneel van opzet zijn (eenmalige meting). Hierdoor mogen eigenlijk geen 
uitspraken gedaan kunnen worden over het verloop in de tijd. Om iets over HPA 
disfuncties in de loop van de tijd te kunnen zeggen zijn prospectieve onderzoeken 
nodig, waarbij proefpersonen meerdere malen worden gemeten in de loop van de tijd. 
 Verder hebben wij bewijs geleverd dat verstoringen van de HPA-as geassocieerd 
zijn met ontregelingen van het metabole systeem wat zorgt voor een groter risico op 
cardiovasculaire zieken. Ook hebben we laten zien dat CRP en cortisol elkaar over en 
weer beïnvloeden wat bijdraagt aan een homeostatisch evenwicht.  
 Onderzoek doen is een ‘never-ending story’; diverse, fascinerende vragen blijven 
onbeantwoord. Dit proefschrift geeft nieuwe inzichten in de relatie tussen 
verstoringen van de HPA-as en het klinisch beeld en metabole en immuunfactoren. 
De puzzel is echter nog lang niet opgelost.  
Ons voorstel is om een dimensionele benadering toe te voegen aan de DSM-IV 
classificatie, omdat dit proefschrift laat zien dat dimensies meer zicht geven op 
onderliggende biologische verstoringen. Er zijn meerdere voordelen te noemen van 
het toevoegen van een dimensionele benadering aan het categoriale DSM-IV systeem. 
De belangrijkste is dat het leidt tot kwantitatieve scores, waardoor ook een ernstmaat 
is meegenomen in het beschrijven van de psychopathologie. Daarnaast voorziet deze 
benadering in een nauwkeurige en consistente methodiek om het klachtenpatroon van 
een individuele patiënt te beschrijven. Een ander voordeel van de dimensionele 
benadering is dat de kwantificatie bijdraagt aan een vergroting van de statistische 
kracht (‘power’) in onderzoek. Je hebt veel meer patiënten nodig om dezelfde statische 
kracht te bereiken met categoriale diagnoses dan met dimensies, er vanuit gaand dat de 
onderliggende psychopathologie continu van aard is. Tot slot is een dimensioneel 
benadering in staat om het non-lineaire aspect van de HPA-as te laten zien. Dit is van 
belang omdat depressieve en angstpatiënten geen homogene groep vormen, ook niet 
wat betreft hun HPA-as disfuncties. Subgroepen van patiënten met hypercortisolisme 
(hoog cortisol) of hypocortisolisme (laag cortisol) zijn aanwezig, waardoor het goed 
voorstelbaar is dat deze subgroepen ook om verschillende soorten (medicamenteuze) 
behandelingen vragen. Overgaan tot een dimensionele uitbreiding voor depressie en 
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angststoornissen (en mogelijk ook andere psychiatrische stoornissen) biedt ook een 
ander perspectief op het probleem van de comorbiditeit, de gelijktijdige aanwezigheid 
van twee of meer stoornissen. Een dimensionele benadering vervangt categoriale 
comorbiditeit door patiëntspecifieke dimensionele profielen.  
 Er is echter nog geen consensus over een eenduidig, gevalideerd, dimensioneel 
model. Deze consensus is nodig om de uitkomsten van verschillende onderzoeken 
met elkaar te kunnen vergelijken. Er moet daarom nog meer werk verricht worden aan 
het ontwikkelen van een valide dimensioneel model voor van depressie en 
angststoornissen. Wij pleiten voor een dimensioneel model met specifieke dimensies 
die het klachtenpatroon van een patiënt goed beschrijven. Daarnaast zijn twee andere 
dimensies van belang: een dimensie die de ernst van het klachtenpatroon weergeeft, en 
een dimensie die de duur van de klachten weergeeft. In dit proefschrift wordt de 
hypothese geformuleerd dat ernst en duur leiden tot opeenvolgende HPA-as 
disfuncties over de tijd, te weten eerst een hyperactiviteit (hogere cortisol afgifte door 
bijnierschors) gevolgd door een hypoactiviteit (lagere cortisol afgifte door 
bijnierschors).  
 Tot slot, voorspellen we een belangrijke rol voor biomarkers bij het diagnosticeren 
van depressieve en angstpatiënten. Het is niet ondenkbaar dat de bepaling van 
cortisolconcentraties in speeksel of bloed in een individuele patiënt in de toekomst 
richtinggevend zal worden voor de keuze van onze medicamenteuze en/of 
psychologische behandeling en voor het voorspellen van het ziekteverloop.  
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